<SEC-DOCUMENT>0000885978-25-000044.txt : 20250811
<SEC-HEADER>0000885978-25-000044.hdr.sgml : 20250811
<ACCEPTANCE-DATETIME>20250811162529
ACCESSION NUMBER:		0000885978-25-000044
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250811
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250811
DATE AS OF CHANGE:		20250811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			U S PHYSICAL THERAPY INC /NV
		CENTRAL INDEX KEY:			0000885978
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HEALTH SERVICES [8000]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				760364866
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11151
		FILM NUMBER:		251202376

	BUSINESS ADDRESS:	
		STREET 1:		1300 WEST SAM HOUSTON PARKWAY
		STREET 2:		SUITE 300
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77043
		BUSINESS PHONE:		7132977000

	MAIL ADDRESS:	
		STREET 1:		1300 WEST SAM HOUSTON PARKWAY
		STREET 2:		SUITE 300
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77043
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:usph="http://usph.com/20250811" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: U.S. PHYSICAL THERAPY, INC.
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_7e35e02eb3b440679f617ee5b3d1a5a9" contextRef="c20250811to20250811" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_a2e4d9c598ba487483fc8aa82102cbb0" contextRef="c20250811to20250811">U S PHYSICAL THERAPY INC /NV</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_a167f776681346a0851f86938d06d9bd" contextRef="c20250811to20250811">0000885978</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="usph-20250811.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20250811to20250811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-11</xbrli:startDate><xbrli:endDate>2025-08-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div>
    <div><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 18pt; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
<div>UNITED STATES</div>
</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 18pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;">WASHINGTON, DC 20549</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;"> <br/>
    </div>

    <div style="text-align: left;"><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_d9d4767fd6d643e593cb717ab15020cb" contextRef="c20250811to20250811">8-K</ix:nonNumeric></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 18pt; font-weight: bold;"> <br/>
    </div>

    <div style="text-align: left;"><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">&#160;</span><span style="font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;">CURRENT REPORT</span></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;">Pursuant to Section&#160;13 or 15(d)</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;">of the Securities Exchange Act of 1934</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;"> <br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_a6a12890b9334edfa3888289aa10c5e1" contextRef="c20250811to20250811" format="ixt:date-monthname-day-year-en">August 11, 2025</ix:nonNumeric></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;"> <br/>
    </div>

    <div style="text-align: left;"><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 24pt;"><span style="font-family: 'Times New Roman',serif; font-size: 24pt; font-weight: bold;">&#160;<span style="-sec-ix-hidden:Fact_a2e4d9c598ba487483fc8aa82102cbb0">U.S. PHYSICAL THERAPY, INC.</span></span></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>

    <div style="text-align: left;"><br/>
    </div>

    <div style="text-align: left;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33.89%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_7191910cbf104527b4da5a81a713f023" contextRef="c20250811to20250811" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric></div>
            <br/>
          </td>

    <td style="width: 1.16%; vertical-align: bottom;">&#160;</td>

    <td style="width: 31.92%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_213251cca7e747ad809c5b90b9feb157" contextRef="c20250811to20250811">001-11151</ix:nonNumeric></div>
            <br/>
          </td>

    <td style="width: 1.12%; vertical-align: bottom;">&#160;</td>

    <td style="width: 31.92%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_3cb6fd416d06454ab267ea8a751fdfe2" contextRef="c20250811to20250811">76-0364866</ix:nonNumeric></div>
            <br/>
          </td>

  </tr>

  <tr>

    <td style="width: 33.89%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 8pt; font-weight: bold;">(State or other jurisdiction</div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 8pt; font-weight: bold;">of incorporation or organization)</div>
          </td>

    <td style="width: 1.16%; vertical-align: bottom;">&#160;</td>

    <td style="width: 31.92%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 8pt; font-weight: bold;">(Commission</div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 8pt; font-weight: bold;">File Number)</div>
          </td>

    <td style="width: 1.12%; vertical-align: bottom;">&#160;</td>

    <td style="width: 31.92%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 8pt; font-weight: bold;">(I.R.S. Employer</div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 8pt; font-weight: bold;">Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 50.44%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_c1e7f97bc7244f64b3ed48451255bb10" contextRef="c20250811to20250811">1300 WEST SAM HOUSTON PARKWAY</ix:nonNumeric>,</div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_373f109e946341e5bceb1cebd1ca8352" contextRef="c20250811to20250811">SUITE 300</ix:nonNumeric>,
              <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_39500760d46a415b9e532222041d50ee" contextRef="c20250811to20250811">HOUSTON</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_a507f61819aa42a1867241fc2610bf6b" contextRef="c20250811to20250811" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric></div>
          </td>

    <td style="width: 1.16%; vertical-align: bottom;">&#160;</td>

    <td style="width: 48.4%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_133af51064f04ce1be51ac6af5f1645e" contextRef="c20250811to20250811">77043</ix:nonNumeric></div>
            <br/>
          </td>

  </tr>

  <tr>

    <td style="width: 50.44%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 8pt; font-weight: bold;">(Address of Principal Executive Offices)</div>
          </td>

    <td style="width: 1.16%; vertical-align: bottom;">&#160;</td>

    <td style="width: 48.4%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 8pt; font-weight: bold;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-weight: bold;"> <br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-weight: bold;">Registrant's telephone number, including area code: (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_d7ba098e84c1432aafd1cc385931a99a" contextRef="c20250811to20250811">713</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_0f3e8a70311541a2b69fbe9748479a6d" contextRef="c20250811to20250811">297-7000</ix:nonNumeric></div>

    <div><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions ( <span style="font-family: 'Times New Roman', serif; font-size: 10pt;"><span style="text-decoration: underline;">see</span></span> General Instruction A.2. below):</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 6.64%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_39af643fc99545a79de5a7906e669420" contextRef="c20250811to20250811" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 93.36%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.64%; vertical-align: top;">&#160;</td>

    <td style="width: 93.36%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6.64%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_2224c71288a443e0ac29addbd2c22ccf" contextRef="c20250811to20250811" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 93.36%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.64%; vertical-align: top;">&#160;</td>

    <td style="width: 93.36%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6.64%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_1877519efbb54991a0940350f1169044" contextRef="c20250811to20250811" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 93.36%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.64%; vertical-align: top;">&#160;</td>

    <td style="width: 93.36%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6.64%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_1dfe45420b104c3baed80ce9e35d5aec" contextRef="c20250811to20250811" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 93.36%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33.64%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #231F20; font-family: 'Times New Roman', serif; font-size: 10pt;">Title of each class</div>
          </td>

    <td style="width: 32.72%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #231F20; font-family: 'Times New Roman', serif; font-size: 10pt;">Trading Symbol(s)</div>
          </td>

    <td style="width: 33.64%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #231F20; font-family: 'Times New Roman', serif; font-size: 10pt;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.64%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_0e70eeca290d4127bca071bb34bf10ff" contextRef="c20250811to20250811">Common Stock, $.01 par value</ix:nonNumeric></div>
            <br/>
          </td>

    <td style="width: 32.72%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_9e83ea122502494c9e122fafb2ecbed8" contextRef="c20250811to20250811">USPH</ix:nonNumeric></div>
            <br/>
          </td>

    <td style="width: 33.64%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_095b2c21c9624aeba7a630a0bce221f2" contextRef="c20250811to20250811" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div>
            <br/>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-align: left; margin-right: 0.8pt; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
      (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18.34%; vertical-align: top;">&#160;</td>

    <td style="width: 22.5%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Emerging growth company</div>
          </td>

    <td style="width: 59.16%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_250369beb79e4c3e95202eac5cd50c53" contextRef="c20250811to20250811" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 80.84%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
              with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</div>
          </td>

    <td style="width: 19.16%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9723;</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; margin-top: 0.75pt;"><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="margin-top: 0.75pt;">
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; margin-bottom: 12pt; font-weight: bold; text-align: justify;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"><span style="font-size: 12pt;">ITEM 7.01 Regulation FD Disclosure. </span><br/>
        </span><span style="font-size: 12pt;">&#160;</span></div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> </span></div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; margin-bottom: 12pt; text-align: justify;"><span style="font-size: 11pt;">On August 7, 2025, U.S. Physical Therapy Inc., (the
          "Company") (NYSE: USPH) hosted a conference call and webcast to discuss its results for the three and six months ended June 30, 2025. The transcript of the conference call is furnished as Exhibit 99.1 to this Current Report on Form 8-K. <br/>
        </span> </div>
<div><span style="font-size: 11pt;"> </span>
       <span style="font-size: 11pt;"> </span></div>
</div>

    <div><span style="font-size: 11pt;"> </span></div>
</div>

  <div><span style="font-size: 11pt;"> </span></div>

  <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 11pt;"> The information in this Current Report on Form 8-K, including the exhibits, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of
      1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the
      Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span><span style="font-size: 11pt;"><br/>
    </span></div>

    <div><span style="font-size: 11pt;"><br/>
      </span> </div>
<div><span style="font-size: 11pt;"> </span>
    <br/></div>

    <div> <br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 11pt; font-weight: bold;">ITEM 9.01&#160;&#160; FINANCIAL STATEMENTS AND EXHIBITS<br/>
    </div>

    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 11pt; font-weight: bold;"><span style="font-weight: normal;"> <br/>
      </span></div>

    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 11pt; font-weight: bold;"><span style="font-weight: normal;">(d) Exhibits</span><br/>
    </div>

    <div style="text-align: left;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 5.78%; vertical-align: middle;">&#160;</td>

    <td style="width: 0.22%; vertical-align: bottom;">&#160;</td>

    <td style="width: 94%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5.78%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 11pt; font-weight: bold;">Exhibit</div>
          </td>

    <td style="width: 0.22%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 12pt;">&#160;</td>

    <td style="width: 94%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 11pt; font-weight: bold;">Description of Exhibit</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5.78%; vertical-align: middle;">&#160;</td>

    <td style="width: 94.22%; vertical-align: middle;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5.78%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt;"><a href="ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 0.22%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 12pt;">&#160;</td>

    <td style="width: 94%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt;">&#160;<span style="font-family: 'Times New Roman',Times,serif; font-size: 11pt;">Registrant's August 7, 2025 Conference Call Transcript Discussing
                Three and Six Months Ended June 30, 2025.<br/>
              </span></div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><br/>
    </div>

    <div><span style="font-size: 12pt;"> </span></div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-size: 11pt;"><br/>
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 11pt; font-weight: bold;">SIGNATURE</div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 11pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
      by the undersigned hereunto duly authorized.</div>

    <div><span style="font-size: 11pt;"> </span></div>

    <div style="text-align: left;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 45.17%; vertical-align: middle;">&#160;</td>

    <td style="width: 1.07%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3.95%; vertical-align: middle;">&#160;</td>

    <td style="width: 0.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 2.68%; vertical-align: middle;">&#160;</td>

    <td style="width: 0.92%; vertical-align: bottom;">&#160;</td>

    <td style="width: 36.68%; vertical-align: middle;">&#160;</td>

    <td style="width: 8.66%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 45.17%; vertical-align: top;">&#160;</td>

    <td style="width: 1.07%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3.95%; vertical-align: top;">&#160;</td>

    <td style="width: 0.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 40.27%; vertical-align: top;" colspan="3">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 11pt; font-weight: bold;">U.S. PHYSICAL THERAPY, INC.</div>
          </td>

    <td style="width: 8.66%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 45.17%; vertical-align: middle;">&#160;</td>

    <td style="width: 5.03%; vertical-align: middle;" colspan="2">&#160;</td>

    <td style="width: 3.56%; vertical-align: middle;" colspan="2">&#160;</td>

    <td style="width: 37.59%; vertical-align: middle;" colspan="2">&#160;</td>

    <td style="width: 8.66%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 45.17%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-size: 12pt;"><span style="font-size: 11pt; font-family: 'Times New Roman',Times,serif;">Date: August 11, 2025</span><br/>
            </div>
          </td>

    <td style="width: 1.07%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3.95%; vertical-align: top;">&#160;</td>

    <td style="width: 0.88%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 12pt;">&#160;</td>

    <td style="width: 2.68%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 11pt;">By:</div>
          </td>

    <td style="width: 0.92%; vertical-align: bottom;">&#160;</td>

    <td style="width: 36.68%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 11pt;">/s/ CAREY HENDRICKSON</div>
          </td>

    <td style="width: 8.66%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 45.17%; vertical-align: top;">&#160;</td>

    <td style="width: 1.07%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3.95%; vertical-align: top;">&#160;</td>

    <td style="width: 0.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 2.68%; vertical-align: top;">&#160;</td>

    <td style="width: 0.92%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 12pt;">&#160;</td>

    <td style="width: 36.68%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt;"><span style="font-family: 'Times New Roman',Times,serif;">Carey Hendrickson</span><br/>
            </div>
          </td>

    <td style="width: 8.66%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 45.17%; vertical-align: top;">&#160;</td>

    <td style="width: 1.07%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3.95%; vertical-align: top;">&#160;</td>

    <td style="width: 0.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 2.68%; vertical-align: top;">&#160;</td>

    <td style="width: 0.92%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 12pt;">&#160;</td>

    <td style="width: 36.68%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt;">Chief Financial Officer</div>
          </td>

    <td style="width: 8.66%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 45.17%; vertical-align: top;">&#160;</td>

    <td style="width: 1.07%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3.95%; vertical-align: top;">&#160;</td>

    <td style="width: 0.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 2.68%; vertical-align: top;">&#160;</td>

    <td style="width: 0.92%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 12pt;">&#160;</td>

    <td style="width: 36.68%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(duly authorized officer and principal financial and accounting officer)</div>
          </td>

    <td style="width: 8.66%; vertical-align: top;">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div><br/>
    </div>

    <div><br/>
    </div>

  </div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.12
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: U.S. PHYSICAL THERAPY, INC.
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <br>
  <br>
  <div style="text-align: justify; text-indent: -107.55pt; margin-left: 107.55pt;"><img height="120" width="241" src="image00002.jpg"></div>
  <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt; font-weight: bold;">CONTACT:</div>
  <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">U.S. Physical Therapy, Inc.</div>
  <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">Carey Hendrickson, Chief Financial Officer</div>
  <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">email: chendrickson@usph.com</div>
  <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">Chris Reading, Chief Executive Officer</div>
  <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">(713) 297-7000</div>
  <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">Three Part Advisors</div>
  <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">Joe Noyons<font style="font-weight: bold;"><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;&#160;</font></font></div>
  <div>(817) 778-8424</div>
  <div><font style="font-weight: bold;"> <br>
    </font></div>
  <div><font style="font-weight: bold;"> <br>
    </font></div>
  <div><font style="font-weight: bold;">Exhibit 99.1 </font></div>
  <div style="text-align: center; text-indent: -108pt; margin-left: 108pt; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;">U.S. Physical Therapy, Inc.</div>
  <div style="text-align: center; text-indent: -108pt; margin-left: 108pt; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;">Conference Call Transcript</div>
  <div style="text-align: center; text-indent: -108pt; margin-left: 108pt; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;">August 7, 2025 10:30 am ET</div>
  <div style="font-weight: normal;"><br>
  </div>
  <div style="font-weight: normal;"><br>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4e350c884da6473fb347febc30048326">

      <tr>
        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Operator: <br>
        </td>
        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Good day, and thank you for standing by. Welcome to the U.S. Physical Therapy second quarter 2025 full year earnings conference call. At this time, all participants are in a
            listen only mode. After the speakers&#8217; presentation, there will be a question and answer session. In order to ask the question during the session, please press star (*) one (1) on your telephone keypad. Please be advised that today&#8217;s conference
            call is being recorded. If you require any further assistance, please press star (*) zero (0). I now would like to turn the call over to Chris Reading, chairman and CEO. Please go ahead, sir.<br>
          </div>
        </td>
      </tr>

  </table>
  <div style="font-weight: normal;"><br>
  </div>
  <font style="font-size: 10pt; font-family: 'Times New Roman',serif;"> </font>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z41bbf63426664e689b32d5417609edc9">

      <tr>
        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading: <br>
        </td>
        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 10pt; font-family: 'Times New Roman',serif;"><font style="font-size: 12pt;">Thank you. Good morning, everyone and welcome to U.S.
              Physical Therapy second quarter 2025 earnings call. With me on the call include Carey Hendrickson, our Chief Financial Officer; Eric Williams, our President and Chief Operating Officer in the East; Graham Reeve, Chief Operating Officer in the
              West; Rick Binstein, our Executive Vice President and General Counsel; Jason Curtis, our Senior Vice President, Accounting and Finance area. Before we begin today&#8217;s call, we need to cover a brief disclosure which I will ask Jason to go ahead
              and read.</font></font></td>
      </tr>

  </table>
  <br>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4079ba7bb8b44baca1a4931a31a8d563">

      <tr>
        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Jason Curtis: <br>
        </td>
        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you, Chris. The presentation includes forward-looking statements which involves certain risks and uncertainties. These forward-looking statements are based on the company&#8217;s
            current views and assumptions. The company&#8217;s actual results may vary materially from those anticipated. Please see the company&#8217;s filings with the Securities and Exchange Commission for more information. This presentation also contains certain
            non-GAAP measures as defined in Regulation G and the related reconciliations can be found in the company&#8217;s earnings release and the company&#8217;s presentation on our website. <br>
          </div>
        </td>
      </tr>

  </table>
  <br>
  <font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;&#160;</font>
  <div>
    <div style="font-weight: normal;">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading: <br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thanks, Jason. So, guys, I want to do this I think a lot like I did it last time, more
                of a candid overview, which allows me to tell the story a little bit better. I want to start out by thanking our partners, our staff, and our home office support around the country who are just doing an excellent job. I&#8217;m going to share
                with you some statistics that we don&#8217;t normally share, we haven&#8217;t shared before, that relates to our patients sentiments around our care. So the clinical staff, our partners they&#8217;re doing a wonderful job. We&#8217;ve had good, strong focus and
                execution in a number of different areas this quarter that we&#8217;ll talk about. Also I want to mention our industrial injury prevention partnerships. Both are really firing on all cylinders at this point. We&#8217;ve added a number of very large
                opportunities, some of which haven&#8217;t even started yet and we continue to be very, very bullish about that part of our business and as we go through the stats you&#8217;ll understand why. So for this second quarter, let&#8217;s talk about physical
                therapy first and volumes. A record second quarter for us. As you guys know, second quarters are typically our busiest quarter in terms of peak volume and so every second quarter pretty much, you know, last year, the same was a record
                quarter for us. . This year, our visits per clinic per day jumped 32.7, up really nicely from again last year&#8217;s second quarter record of 30.6. So the drivers around this, I think more than anything are happy patients who love us at the end
                of their care, who refer their family and friends and neighbors to us and when pickleball happens, a year or two down the road, they come back and see us. This is the stat that I want to share with you that we haven&#8217;t really talked about
                before. It&#8217;s not a new stat for us. We measure it every quarter. We have an outside company tabulate our surveys. This is companywide. Our net promoter score is 93.5. Just to give you some perspective, before this call, I googled, What&#8217;s a
                good net promoter score for a healthcare company, and I got two answers: good was 30 and excellent was 50. So, the way that we get results tabulated, we&#8217;re able to see what percentage of patients are active promoters of our business, and we
                are at 95%. Only 1% of our patients has a negative or detractor. So that puts us in amazingly good standing and in an amazing category. Part of the reason for our success obviously is what we try to do everyday. On the injury prevention
                side, again, I can&#8217;t say enough good things about our teams. Both partnerships are doing really well. Revenue&#8217;s up 22.6%. Gross profit is up 25.8% compared to the prior year quarter and again we are working on some really large contracts,
                one new in the auto industry; actually several new, many, one really large and one very large one to come here later in the year. Revenues in PT were also strong, increasing 17.3%. We added over 50 net clinics compared to the prior year
                period. For the first time, through the first six months, we&#8217;ve exceeded three million visits year-to-date so far. We were also able to drive a slight increase in our net rate despite the Medicare headwinds which you guys know all too well
                about. I just want to point out if you go back to when just the period before these Medicare cuts started, which would have been sequential layered cuts for a number of years, the impact in this year from those rate cuts is right around $25
                million and that&#8217;s straight off the profit line. It&#8217;s been a huge impact that&#8217;s been a major headwind on a year-over-year basis. I can&#8217;t remember exactly, Carey can tell us, but between $5 and 6 million compared to last year and this year.
                That&#8217;s 8%, 8.5% of our earnings on last year&#8217;s number, maybe a little bit more than that. And so to grow over 20% with that kind of a headwind consistently, we&#8217;re really happy right now about things that are coming together. Our costs, our
                salaries and related costs was up on a per visit basis ever so slightly, less than 1%, but our overall cost per visits was down slightly and really, I think beginning March and continuing forward, we&#8217;re beginning to get traction on a number
                of new initiatives that we&#8217;ve been working on that will help us impact cost, that will help us continue to drive more volume, and we&#8217;re feeling better about things right now than we have for some time. When you look at PT, our gross profit
                margin and we&#8217;re going to say adjusted very, very slightly, I think around a couple of hundred thousand dollars only relating to an incentive payment that Metro had as a result of closing that deal. Our gross profit margin came in at 21.1%
                for the quarter. So that&#8217;s a nice move forward as well. On the development front, we&#8217;ve added a homecare business, a couple of physical therapy acquisitions, and we have more to come the remainder of the year. We intend to focus hard on our
                injury prevention business given the organic and the overall growth elements in that business, the margins, and the performance of both those teams. We have widened our industry verticals in that space. We have widened our service offerings
                in that space. We&#8217;re competing and winning large contracts. We are able to do that with some margin improvement as well. So that business is very strong for us and has continued to be strong really for a very long time. <br>
                <br>
                The combination of these positive factors has caused us to look out over the remainder of the year and increase guidance, which is now between $93.0 and 97.0 million in adjusted EBITDA. Before I turn over to Carey because I skipped through
                a lot of things, I wanted to tell the story. Carey&#8217;s going to go through the numbers with a little bit more granularity. Again, I just want to thank our teams. We endeavor every day to try to make a difference, to try to make a positive
                impact in our patients&#8217; lives or within the injury prevention space and in the lives of the workers who are working at our nation&#8217;s largest and most prestigious companies. We&#8217;re having an impact. We&#8217;re making the world in our little way
                better and we feel really good about that and so again, I want to thank everybody that&#8217;s involved in that. It&#8217;s making a difference, and we appreciate it very much. Carey, if you would go ahead.<br>
              </font><br>
            </td>
          </tr>

      </table>
    </div>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Carey Hendrickson:&#160;&#160;&#160; <br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Great, thank you, Chris and good morning, everyone. As Chris mentioned, we are very pleased with our second quarter results and there are a few performance metrics that stood
              out to me. We achieved a new record, a company record of 32.7 average visits per clinic per day. That was the highest in our history. Our salaries and related costs, as Chris mentioned, increased slightly, just 0.7% compared to the prior
              year. That is the smallest increase in that metric we&#8217;ve had since the fourth quarter of 2023. Our total operating cost per visit actually decreased year-over-year. Our PT margin, as Chris noted, improved to 21.1%, up from 20.1% in the second
              quarter of last year. Our IP revenue excluding acquisitions, so on an organic basis, grew 18.4% and our IP gross profit increased 21.8% on an organic basis. Our adjusted EBITDA increased to $26.9 million in the second quarter of 2025 which
              was up $4.7 million from the second quarter of last year and then our adjusted EBITDA margin expanded to 17.5%, up from 16.4% in the second quarter of last year. So, all of those metrics I was really pleased with. Turning to patient visit
              volume, our average visits per day was 33.0 in April. They were 32.9 in May and 32.3 in June. That slight tapering in June is consistent with our historic summer patterns when volume dips slightly in the summer months before rebounding again
              in mid-August. <br>
              <br>
              We recorded 1,530,263 clinic visits in the second quarter and then also had 28,493 home-care visits. This is the first time we&#8217;ve reported home-care visits separately from our in-clinic visits. They stemmed from the home-care business that we
              acquired through the Metro PT transaction in New York in the fourth quarter of last year, and we&#8217;ll continue to report those separately going forward. For reference, we had 22,943 in home visits in the first quarter of this year, and that
              number is &#8211; the year to date numbers are in the release, too, just so you&#8217;ll have that going forward. Our net rate per patient visit was $105.33. That&#8217;s ahead of the $105.05 we achieved in the second quarter of last year, but it is slightly
              less than what we had in the first quarter of $105.66. As a reminder, we absorbed the 2.9% Medicare rate reduction that took effect at the beginning of the year. Also, our largest payer in Michigan, which is our third largest state with 56
              clinics, implemented a policy change on April 1 that negatively impacted our net rate a little bit in that state. So that was a bit of a headwind too. With those headwinds, our net rate held up well in the second quarter and we expect it to
              grow from there. We continue our efforts to have a strategic focus on increasing reimbursement rates through targeted contract negotiations, as well as efforts to grow our higher net rate worker&#8217;s comp business. Worker&#8217;s comp represented
              10.4% of our net patient revenues in the second quarter with visits increasing 8.4% year-over-year. We&#8217;re fully committed to all of our rate-enhancing initiatives and we&#8217;re working on those every day. Physical therapy revenues were $168.3
              million in the second quarter of 2025, which represented a $24.8 million or 17.3% increase compared to the same period last year. The majority of that growth was driven by acquisitions completed since the second quarter of last year. Most
              notably, that Metro acquisition that we made in New York last November, that was $19.6 million of the $24.8 million. Physical therapy operating costs were $133.1 million. That was an increase of $18.4 million or 16% over the prior year
              quarter. Importantly, we managed our costs effectively. Our salaries and related costs, as I&#8217;ve mentioned, were just up 0.7%, at $60.80, and our total operating costs, as I also mentioned, were actually down year over year. Our physical
              therapy profit margin, as I&#8217;ve noted already, 21.1%, that&#8217;s our highest quarterly margin since the second quarter of 2023. That, of course, reflects solid revenue growth and good cost management.<br>
              <br>
              Our IIP team delivered another strong performance in the second quarter. Our IIP net revenues increased $5.3 million or 22.6% compared to the second quarter of 2024, and income rose $1.3 million or 25.8% of the prior year quarter. Then I gave
              the organic numbers earlier, IIP revenues increased 18.4% and gross profit at 21.8%. The IIP margin for the second quarter was 22%, which is up from 21.4% in the same quarter last year, reflecting strong top-line growth and continued focus on
              operational execution.<br>
              <br>
              Our corporate costs remained in line with expectations. They were 8.7% of net revenue in the second quarter, and that compares to 8.5% in the second quarter of last year. We&#8217;re in the early stages of implementing a new enterprise-wide
              financial and human resources system. Implementation costs related to that project will continue through 2026, and consistent with our practice for similar non-recurring costs, we&#8217;ll add those costs back in our adjusted EBITDA calculations.
              Year to date, we&#8217;ve incurred $221,000 in implementation costs. That was really related to the selection part of our implementation and we&#8217;ll start our implementation in the third quarter. That will always be itemized in our non-GAAP
              reconciliation page.<br>
              <br>
              Operating results were $12.4 million, up from $11.0 million in the second quarter of last year, and on a per share basis, we were $0.81 versus $0.73 in the prior year quarter.<br>
              <br>
              Our balance sheet remains in excellent shape. We currently have $135.0 million in our term loan with a swap agreement in place that fixes that interest rate at 4.7% that extends through mid-2027. In addition, we have a $175.0 million
              revolving credit facility that had $24.5 million drawn as of June 30, 2025. We ended the quarter with $34.1 million in cash. As disclosed in our earnings release, the board of directors authorized a share repurchase program this week,
              providing us with the flexibility to repurchase up to $25.0 million of our shares through December 31, 2026, if market conditions are appropriate. We view this as a prudent tool to have at our disposal, However, acquisitions will continue to
              be our primary capital allocation priority, consistent with our growth strategy.<br>
              <br>
              Our performance in the first half of the year has been strong, exceeding our expectations coming into the year, and we believe we&#8217;re well-positioned for a solid second half as well. As a result, we raised our full year 2025 adjusted EBITDA
              guidance from a range of $88 million - $93 million to the new range of $93 million - $97 million dollars. In effect, the high end of our prior range becomes the low end of our new range with a $4 million increase at the top. <br>
              <br>
              So with that, I&#8217;ll turn the call back over to Chris.<br>
              <br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thanks, Carey. I appreciate it. I want to mention one more thing. We&#8217;re happy with where we are this quarter and the progress. We still have plenty of things to work on, right,
              which to me, is also encouraging because we&#8217;re not there yet. We have room for improvement. One of those things I want to point out, as a matter of perspective, relates to our same-store visit growth with mature facilities, which this quarter
              was a little bit lighter than maybe everybody expected. It was over 1% but not what I would call our normal rates. We still have a few markets where staffing is a little tight and with cost control, it probably put a little of a bit of a
              dampener on us. I want to point out one thing. Back in the spring, we initiated a staged rollout of cash based programs. We haven&#8217;t spent a lot of time talking about it. As with anything, it takes a little time to get traction. We&#8217;re getting
              real traction with that now. This doesn&#8217;t show up as additional visits. Although, some of our patients are coming in for these cash based services. We have generated about $900,000 worth of additional revenue, a lot of that coming from our
              cash based services which are continuing to ramp up as we go forward. So that&#8217;s an added benefit that we really haven&#8217;t had before. We&#8217;ve seen some of our partnerships do extraordinarily well with that.<br>
              <br>
              So with that, that concludes our prepared and our candid comments and we&#8217;d like to go ahead and open it up for questions.<br>
              <br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Operator:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you. At this time, if you would like to ask a question, please press star (*) one (1) on your telephone keypad. You may remove yourself from the queue at any time by
              pressing star (*) two (2). Once again, that is star (*) one (1) to ask a question. We will pause for a moment to allow questions to queue. Our first question will come from Bryan Tanquilut with Jefferies. Your line is open.<br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">&#160;Bryan Tanquilut:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">Hey. Good morning, guys, and congrats on a solid quarter. Chris, maybe I&#8217;ll start with a follow up or a question around your
              last comments. As I think about same-store outlook, how would you characterize demand for your services, or just broadly in the market, versus, like you were saying, kind of like pulling back and managing the cost because of the clinician,
              the labor situation? Then, maybe how do you think about your capacity versus thinking about maybe de novo builds in the future as you start bumping up against capacity constraints potentially?</font><br>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:&#160;&#160;&#160; <br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes. Well, demand is really solid pretty much everywhere. Now, there is a little push-pull that we may have to manage always when we&#8217;re trying to get cost under control and so
              you&#8217;re trying not to be fat, to use that term, to have too many slack resources, yet you&#8217;re still trying to meet demands. Certainly, it&#8217;s not perfect. We have some markets where the markets are still a little tight where we have additional
              FTEs we need to hire. That is where the demand is strong and yet, we need some more resources. Other places are being dialed in where they need to be. So, that&#8217;s a work in progress. The cash based programs are helping us to generate
              additional revenue, and so that has been kind of a net add for us that we haven&#8217;t had before. I&#8217;m trying to remember the second part of your question.<br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Byran Tanquilit:&#160; <br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Just what do you think about capital deployment in maybe de novos as you start bumping up against&#160; capacity constraints?<br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">On the de novo side, look, we&#8217;re going to &#8211; we&#8217;ve had this market where we&#8217;ve had some headwinds and we had to deal with that. This is going to be probably the strongest de
              novo year that we&#8217;ve had since I&#8217;ve been with the company. So, de novos are going to be good this year. They are on a good pace. We were making adjustments and have made adjustments on the recruiting side of the house, on the residency side,
              which get more students into our programs. So, we think we&#8217;ll be able to continue to ramp into the demand. We just have to keep it dialed in right now, but I don&#8217;t see it impacting our de novo openings.<br>
              <br>
              Frankly, in markets in New York where net rate is considerably higher than most of our competition,&#160;&#160; our small competition,&#160; We&#8217;re able to do these small acquinovos which frankly, we don&#8217;t even announce, but we&#8217;re able to do those at very,
              very nice multiples and get a nice rate lift as a result and a lot more resources to help them grow in scale, so that is going to continue to be strong as well.<br>
              <br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Brian Tanquilut:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Chris, to follow up on that, we think capital at this point, obviously the announcement, the dividend is positive, so just curious how you and the board thought to introduce a
              dividend just when it sounds like this is going to be one of your best de novo years. Maybe you just think about the balance sheet, the cash generation, and then yes, just the decision to do by that. <br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes. So you mentioned dividend, the dividend is ongoing and so we&#8217;ve been paying the dividend for a long time. <br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Brian Tanquilut:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yeah sorry. I meant the buyback.<br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">The buyback is new. Look, we feel like the stock&#8217;s been undervalued for some time. We understand healthcare services, you know, are having a little bit of a tough year. We&#8217;ve
              had some Medicare headwinds and yet we&#8217;re making progress and continuing to grow the company. So we wanted to be in a position to have flexibility at a certain level where we could go in and demonstrate our belief that we&#8217;re going to continue
              to grow this company and do it well over time. So it gives us flexibility. As Carey mentioned that&#8217;s not our first preference for capital deployment. I will say our first preference right now, frankly, is directed towards injury prevention
              where the embedded organic elements of that business are really, really strong. The next would be PT and then on from there. We&#8217;ll be disciplined about any share buyback and it&#8217;s going to be dependent upon other capital demands and really
              where the stock is at any given time.<br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Brian Tanquilut:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Got it. Chris, if I may throw one more question, I think about just the efficiency of your physical therapists, we hear about A.I. tools in the market aimed at physical
              therapists. Is that something that you&#8217;re throwing in the mix that&#8217;s helping you out, and maybe kind of related, you talked about your home PT business, just if anything, is out there that you can share with us in terms of dynamics there
              because, obviously, it&#8217;s new to us and investors on what that business looks like? Thank you.<br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes. There are some cool A.I. tools right now. We&#8217;re deploying A.I. backed technologies for clinical documentation which is helping people get through their least favorite
              thing of the day, if you are a clinician, which is to document all the services that you did with somebody. In physical therapy, you have to document a lot of things, set some reps and weights and motions and joint related movement. It&#8217;s
              tedious. It takes time. So this ambient listening A.I. driven assist is helping our clinicians get through that much quicker, much more efficiently. We&#8217;re just on the front-end of rolling it out, but that&#8217;s been well received. We&#8217;re rolling
              out what I would call broadly, semi-virtualization of the front desk which enables us, not to go completely virtual because I don&#8217;t think we&#8217;re ready for that yet nor do I think patients are ready. But an augmented situation where we&#8217;re able
              to focus efforts from across multiple clinics to through the individual that maybe onsite or remote somewhere and be much, much more efficient and save a number of front desk FTEs, which continue to be a labor challenge just in terms of
              longevity, unlike our PT licensed folks, which frankly right now we&#8217;re having the best least amount of turnover that we have seen in maybe my recollection, really good right now. So these tools are helping us get some margin and efficiency in
              areas where we just haven&#8217;t been able to do that in the past. We&#8217;re early but it&#8217;s directionally encouraging.<br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Brian Tanquilut:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you.</font><br>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thanks Brian,<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
  </div>
  <div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><font style="font-size: 12pt;">Operator:&#160;</font>&#160;&#160;


                <br>
              </font></td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><font style="font-size: 12pt;">Thank you. Our next question comes from Joanna
                  Gajuk with Bank of America. Your line is open.</font><br>
              </font></td>
          </tr>

      </table>
    </div>
  </div>
  <br>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Joanna Gajuk:<br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Hi. Good morning.<br>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:&#160;&#160;&#160; <br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">Hi, Joanna.</font><br>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Joanna Gajuk:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thanks for taking the question. Hi. So maybe first on the metric that really stood out besides the visit per clinic, but the cost per visit by a decline , right? So maybe in
                that context, can you walk us through or give us some update on your labor management strategies, the wage, maybe talk about turnover and other, I guess, metrics you can share? It sounds like you&#8217;re doing pretty good job there.<br>
              </div>
            </td>
          </tr>

      </table>
      <br>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Eric, you want to go ahead and take that, talk about turnover and some of the things we&#8217;re working on.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div>
        <div><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Eric Williams:<br>
              </td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes. This is &#8211; again you recall from our quarterly conversations here, we made a lot of investments in systems and resources in 2024 that are really starting to pay
                  dividends for us in 2025 as it relates to recruiting and retention. We&#8217;ve seen a 25% increase in student rotations across our partnerships in 2025. Part of that was participating in a student rotation matching program with software, the
                  exact software that&#8217;s been used by all of the PT schools out there. So we&#8217;ve seen almost a 200 student pickup this year. We put it in our new applicant tracking system. In 2024, that&#8217;s also giving us better company wide visibility across
                  our partnerships to all the applicants who are applying for jobs and it gives us better opportunities to follow up with these applicants, track them pre-hire, post-hire, and then for the ones, of course, that don&#8217;t take jobs with us, we
                  have this huge database that we&#8217;re building up of people that we can go back to when we do have job openings. <br>
                  <br>
                  So, systems made a big difference, putting in some additional resources to help us on the recruiting front made a big difference for us, and the mentorship piece, it&#8217;s a focus for us. We really push it hard to make sure that we&#8217;re
                  connecting and spending time with the younger therapist that we bring on board in order to reduce turnover rates. As Chris mentioned, these are the lowest turnover rates we&#8217;ve seen for the six months this year, January through June.
                  Lowest numbers we&#8217;ve seen in the last seven years. So it&#8217;s absolutely making an impact for us that the pieces that we&#8217;re really excited about, and Chris referenced one of them, I&#8217;ll touch base on that in a second, this mentorship piece,
                  while we&#8217;re really focusing it at a partnership level which is where our clinical staff goes to work, when the process of building out a platform here, a software platform that&#8217;s going to allow us to expand our mentorship programs beyond
                  the four walls of the corner and beyond existing partnership. It&#8217;s going to give us the ability to connect 2,600 clinicians across our company with each other so that people that have a particular interest or specialty have an opportunity
                  to connect with people that might not have that specialty within the partnership, but have an expertise and we can take advantage that across our entire company. So we&#8217;re excited about that. We think that will pay dividends for us as well
                  as it relates to our ability to retain staff. Those are the big ones. <br>
                  <br>
                  Chris, you mentioned A.I., I&#8217;ll talk about that as well. So, we are in the early innings of using that voice recognition technology that Chris talked about. I think we have that in the hands of 200 or 250 PTs right now. It&#8217;s been really,
                  really well received. I think that is going to have an impact for us over time, with retention as well. If you can reduce documentation, the things clinicians&#160; hate&#160; to do the most, right now, there&#8217;s a lot of people that are dabbling in
                  it.&#160; I think we&#8217;re farther ahead experimenting with that right now, I think that is going to help us attract and retain staff going forward. <br>
                </div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Joanna Gajuk:<br>
              </td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Crosstalk<br>
                </div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Eric Williams:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Go ahead. I&#8217;m sorry.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Joanna Gajuk:<br>
              </td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">Are you willing to share the turnover, the&#160; actual turnover, a number? </font><br>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Eric Williams:<br>
              </td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">We will report that publicly at the end of the year, and you&#8217;ll find that in our ESG Report.</font><br>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:&#160;&#160;&#160; <br>
              </td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                <div style="text-align: justify; text-indent: -108pt; margin-left: 108pt; font-family: 'Times New Roman', serif; font-size: 12pt;">Joanna, we don&#8217;t want to be in a position quarter to quarter to add to our already exhaustive list of metrics
                  but we&#8217;re in a good spot right now. We&#8217;re in a really good spot.<br>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>

    </div>
    <div>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Joanna Gajuk:<br>
                </td>
                <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">I<font style="font-size: 12pt;">t sounds like it. Thank you. If I may have another topic, Medicare rates, right, have been a headwind for a couple of
                    years. It sounds like 2026 is going to be better.&#160; So the overall physician fee schedule is going up like 2.5% or more, 3.6%, 3.8%. We had estimated like 2.5% or so for physical therapy codes. Can you talk about your estimate for your
                    company in terms of how the rate increase would&#160; translate for your portfolio into next year? Thank you.<br>
                  </font></td>
                <font style="font-size: 12pt;"> </font></tr>
              <font style="font-size: 12pt;"> </font>

          </table>
          <font style="font-size: 12pt;"> </font></div>
        <font style="font-size: 12pt;"> </font>
        <div><br>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                </td>
                <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">Let me make a quick comment then I&#8217;m going to kick it to Carey and he&#8217;ll get you
                    through the specifics. This year, and this is a proposed rule, so it&#8217;s going to be a lot of commentary and certainly a lot from PT industry. This year was the most complicated of any year that I can remember, literally, in my career.
                    They changed a lot,- think about turning, kind of, metaphorically turning knobs, they turned a lot of different knobs for our RVUs, for work values, for geographic index factors and there are particularly large swings, on the geography
                    side. Some so much that both us and the APTA thought that some of the tables weren&#8217;t correct.<br>
                    <br>
                    So, our overall assessment is, Carey can get in to, but the takeaway is positive, no longer a headwind.&#160; We haven&#8217;t had any kind of a tailwind in a while. We&#8217;re happy that it&#8217;s forward but we think, there&#8217;s more work to be done,
                    obviously with CMS. Carey, why don&#8217;t you go to the specifics. </font><br>
                  <br>
                </td>
              </tr>

          </table>
        </div>
        <div><br>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Carey Hendrickson:<br>
                </td>
                <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">Y<font style="font-size: 12pt;">es.</font> Thank you. So, Joanna, we&#8217;ve looked at
                    it, looking at the various geographies and what the changes were in the geographies, as Chris mentioned, and that that varies a lot. Based on where we are and the rate increases in those geographies, I think we&#8217;re probably going to be
                    somewhere between a 1% and 1.75% increase, something like that. For us, again, positive. We're happy to have a positive increase and not be looking at negative numbers for next year, so we're really pleased about that. That one point,
                    you know, if it's in that 1 to 1.75% range, that would be somewhere between $2 and $3 million of a positive for us next year on the top line. And then, from an EBITDAstandpoint, it would translate somewhere between $1.5 and $2.5
                    million. So, in that range is kind of what we're looking at this point. Again, this is a preliminary ruling. We'll know the final ruling in December, and we'll see if anything changes, but that's kind of where we see it today.<br>
                  </font></td>
              </tr>

          </table>
          <font style="font-size: 12pt;"> </font></div>
        <div><br>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Joanna Gajuk:<br>
                </td>
                <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">All right. This is very helpful. Thank you. Again, so, you made it sound like there's going to be pushback on that level,
                    so is it your expectation maybe the final is a little bit better than the proposal, or I guess is it too early to say?</font><br>
                </td>
              </tr>

          </table>
        </div>
        <div><br>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                </td>
                <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                  <div><font style="font-size: 12pt;">Yes, we certainly hope that it will be. You know, the irony is, unfortunately, if you get under the hood and see how the sausage is made, that the specialties that have the most extraordinary increases
                      in the cost of equipment, so very expensive equipment, and have the most highly litigated areas where there's exposure to litigation and other things, which, you know, the number of patients that love us on a percentage basis,
                      physical therapy in general, doesn't have that problem. So, we're making a decided push where we know that we've made the system a lot of money.&#160; In fact, the state of Maryland where physical therapy on a pilot program of CMS is in
                      the position as kind of a primary care for musculoskeletal, the physical therapists determine what happens in the case.<br>
                      &#160;&#160;&#160; <br>
                      There&#8217;s a massive aggregate savings and we&#8217;re hoping to use those results with CMS to extend that pilot beyond the state of Maryland, which could be a big pay for a reasonable rational annual cost of living increase for the fee
                      schedule. And we think we should be front and center on that. So yes, we&#8217;re pushing. We hope it gets better. We think there&#8217;s some flaws in the existing methodology and we&#8217;re going to be working on that between now and year end.<br>
                    </font><br>
                  </div>
                </td>
              </tr>

          </table>
          <font style="font-size: 12pt;"> </font></div>
        <font style="font-size: 12pt;"> </font>
        <div><br>
        </div>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Joanna Gajuk:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">Great. I appreciate the call. Thank you so much. </font><br>
            </td>
          </tr>

      </table>
    </div>
    <br>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thanks, Joanna.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Operator:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you. Our next question will come from Benjamin Rossi with J.P. Morgan. Your line is open.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Benjamin Rossi:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Hi. Good morning. Thanks for taking my question here. So, turning to the IIP segment performance, you mentioned adding some services here over the course of the year. It
                certainly seems to be off to a strong start in the first half with margins expanding year over year. Is it fair to say that that segment is coming in ahead of your initial expectations of a $3 million absolute increase in gross profit,
                particularly as we head into the seasonally stronger 3Q?<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes, I don't have in front of me exactly what our budget was, but we're definitely ahead of budget for the year. You know, Q2 second half is a little different seasonal
                pattern with injury prevention. We tend to be pretty strong through the year, a little light in January like everywhere else, and a little light in December where I think some of the big auto manufacturers, some of the nation's biggest
                manufacturers, there's an early shutdown in December, and so that impacts our earnings a little bit. But if you go back, not just this first half or this quarter, but on a year-over-year-over-year basis, injury prevention has really done
                well for us and has really strong organic growth attributed to it. So, we continue to be bullish. We're spending more time in development in that area, and we're identifying good companies. And, of course, like anything else, we've got good
                things done, but we expect to continue to deploy capital directionally there.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <br>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Benjamin Rossi:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Got it. And I think if this is a follow-up to your comment on Medicare PFS rates, obviously it seems like the change in 2026 is more of a one-time fix and doesn't necessarily
                address anything in 2027 and doesn't obviously dig you out of that $25 million hole you described after decreases in recent years. Can you walk us through where your conversations stand with your counterparts at the federal level and maybe
                how they're framing the decision to include that one-time fix for 2026?<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes, I think it depends on who you talk to, but nobody in Congress is happy that this is an annual issue. But this isn't the only annual issue that the government faces these
                days. It seems like that's how we fund the government each year is through this crisis management process, that eventually ultimately gets done with a lot of chicken on both sides. So, it's not the optimal way to do anything, it's certainly
                not fair to providers to have a one-month runway, basically, where you're notified in December what the final decision is, and then you have until all of January through the holidays to get things ready to go. We should have a multi-year
                plan. It should be locked. All of the lawmakers believe that's the way it should be. And yet, I've had people call it a ten-year permanent fix on the Physician Fee Schedule, about a $100 billion event. So, they need savings to be able to do
                that. One of the big areas that we think is a saver, and we're through APTQI, the Alliance for Physical Therapy, Quality, and Innovation, a group that I'm heavily involved in with all the other big companies in PT, we're going to have a
                pretty significant spend this year to use an outside Beltway analytics group to take the results that we've seen from the EQUIP study in Maryland and extrapolate those real results, not theoretical, but actual, over the nation and create
                what we think is a massive savings for the system with physical therapists in that key role as kind of the primary care director of the musculoskeletal case. So, that's a possible pay-for, a Physician Fee Schedule fix. It's gotten a lot of
                very positive attention among our lawmakers and our Congress on both sides. CMS, I would tell you, is kind of a difficult place to be because it's so siloed. So, people have one infinitesimally small fraction of what amounts to a very
                complicated series of areas and rules and responsibilities. So, it's a little bit different to get a clear picture there, a little bit difficult. But with Congress, as long as we can come up with some savings, we can get out of this deficit
                spending that we're in, maybe hear about tariffs and all the revenue that's created, we'll see. But we need more than one year fix, for sure. And we have AMA and the Hospital Association and everybody else wants more than a year-to-year
                fix. It's unsustainable. <br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Benjamin Rossi:&#160;&#160;&#160; <br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Great. Thanks for the additional commentary here. <br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Operator:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you. Our next question will come from Larry Solow with CJS Securities. Your line is open.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Larry Solow:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Good morning, guys. Thanks for the question. Most of my questions have been actually answered. I'm just curious, so the 7% or nearly 7% year-over-year increase in just visits
                per day per clinic and also the very modest growth in labor, how much of that just relates to the acceleration of closures last year? I know you closed like 30 clinics at the end of Q3, I think. So, it feels like a lot of that, just more
                efficiencies driving these gains. Is that fair to say? The second part of the question is I know you had set out, you discussed last year some cost-cutting initiatives. You never really put a number on it, but you sort of thought you could
                add up to maybe a double-digit million over time. So I'm curious how that is played into the performance this quarter.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes, it's like baking a cake. There's a lot of ingredients that go together, and at the end of the day, you hope it tastes good. I don't have in front of me the relative
                pieces, parts of every one of those ingredients that are blended together, so it's a little bit hard to measure. Cost efficiencies, on one hand, create both challenges and opportunities sometimes in terms of volume-related aspects. So,
                we're trying to do the best we can to balance technology, efficiency, appropriate levels of labor, which minute-to-minute are never perfect. Perceived demand, expansion, it's pretty complicated. It's running a business and there are a lot
                of moving parts. So all those things are coming together. What you're hearing is we're feeling more confident that the things that we've done, which again, as you point out, are multifaceted, are coming together in the right way. But as I
                pointed out earlier, it's not perfect. We still have plenty to work on. There's still plenty of opportunity, being focused on it, but where we are feels a little better than where we've been for maybe a while now.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Carey Hendrickson:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Right. And factoring into the visits per day growth is the addition of Metro in November. And so, it's been higher since that point in time. We were probably running at about
                31 before, and then that's kicked up a little bit, because they average about 45 visits per clinic per day there at Metro. But there's still really good growth in that overall visits per clinic per day.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Larry Solow:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Good, well, that's a good segue then, Carey, into Metro, because I know that was your, I think, your biggest acquisition historically. So, curious, it sounds like that's
                progressing really well. And I know when you acquired at the time of the acquisition, you spoke about a lot of opportunities, and I guess this acquinovo&#160; opening sounds like that's happening at Metro. And I assume since New York has better
                &#8211; one of the better rates, that probably benefits you guys disproportionately too.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes, we have a strong team there. Michael and his team are strong. They're very strong. Clinically, they're strong operators, they're strong in development. And so, yes,
                we've got plenty of opportunities to chew on and work our way through for what should be a long period of time. Acquinovos being just one of those. So, they're doing well.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Carey Hendrickson:&#160;&#160;&#160; <br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes. And Larry, one of the things that's been really positive there and we've talked about this before is the net rate increase we've seen at Metro since we acquired them.
                That's one of the things that we do with acquisitions, we look at trying to increase their contracts as we bring them over. When we first &#8211; the first month for Metro was around a $101.00 net rate, and that increased to an average of $104.50
                in the first quarter, and it was $107.50 in the second quarter. So, we've really seen some nice rate improvement there. That doesn't show up in the mature clinics line, instead it shows up in the clinic additions line. But I just wanted to
                point out that we're seeing really good net rate increases there at Metro. So, that's helpful as well.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Larry Solow:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">And could you just walk through just the pricing breakout in the quarter? I guess, do you discuss that? Usually, you give us what commercial pricing was in the quarter. I
                heard you discuss the workers comp piece. Did you give any more details on the commercial side?<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Carey Hendrickson:&#160;&#160;&#160; <br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">Sure, I'm sure happy to look at that. So, with 105.33 overall, commercial rates were about around 105.50. We had a nice
                increase in commercial rates. Medicare is a little north of 92. Workers comp was still a little bit north of $150.00 per visit, which is really good. So, those are the three primary categories. The others were relatively stable as well,
                Medicaid, personal injury, self-pay.</font><br>
            </td>
          </tr>

      </table>
    </div>
    <br>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Larry Solow:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">Great. Okay, appreciate it. Thanks, guys.</font><br>
            </td>
          </tr>

      </table>
    </div>
    <br>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thanks a lot.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Operator:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you. Our next question will come from Jared Haase with William Blair. Your line is open.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Jared Haase:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Hey, good morning. Thanks for taking all the questions. Chris, maybe for you, I wanted to ask another one on the IIP segment, and nice to see the continued momentum there. I
                think you mentioned a number of larger opportunities that haven't started yet. So, I'm wondering if there's any way that you can contextualize, I guess, what that backlog looks like, or any way to frame up what the incremental revenue
                opportunity is and how that might compare to prior years.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes, I don't have it. Jared, I don't have it in front of me. My preference, and maybe I need to be a little bit careful, my preference is to not count revenue ahead of when
                we've generated it, either in development or otherwise. We're definitely making progress. We&#8217;re having a good year. Frankly, it's all about staffing, and the team's done a fantastic job, both with the auto industry major contract that we
                got where we needed to hire 50, five zero FTEs to staff that opportunity. But if we hadn't hired 50, if we'd only hired 20 or 30, the revenue generation compared to the potential would have been different. So, I really can't afford to be
                that far out on a limb, and don't want to be in, so we're not going to do that. But as that comes about and we're realizing it, I'm happy to talk more about it once it actually happens.<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Jared Haase:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes, that's fair. Totally makes sense. Maybe I'll ask a follow-up. I think you all have made some public comments in the past about some of the virtual PT applications that
                are out there, and I think recently one of the larger ones announced they're building out sort of a network of in-person providers as a way to supplement their digital offerings. So, I'm wondering if you have any more that you can say about
                that. Would you consider participating in a virtual network like that, or excuse me, in a network like that with a virtual partner? How are you thinking about maybe the potential opportunity in terms of, call it, patient acquisition or
                opening up any referral channel?<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes. Well, again, I don't want to speculate too much in hypothetical situations. Have we had discussions with one or more providers about providing a brick and mortar
                opportunity in person to add to a virtual offering? Yes. It remains to be seen whether that's something that the industry is accepting of or not. And I say that because a lot of the virtual providers have sold &#8211; I'm going to use air quotes,
                the &#8220;PT service&#8221; at a very low cost, kind of a per member pricing level, very generic, not delivered by therapists. It's delivered either through an app or backed up by call center employees who, again, for the most part, aren't licensed
                clinical folks, they follow the script. And so, what's been sold is that they can take all-comers and any diagnosis and very complicated things, post-op reconstructions and rotator cuff repairs, and frankly, I'll tell you my opinion is, is
                that can't be done efficiently or effectively. And so, I think they are in a tough spot where they have to figure out whether there's the bricks and mortar solution. <br>
                <br>
                Reciprocally, we are now using technology through companies like Limber, who's been a nice partner for us, that has an augmented solution that we use with our patients to be able to go into their home and see them complete their home
                program, and actually see objective measures of motion and activity and other things which help us better, be better informed to guide that care. There will be a point in time, and we're not there yet because we're working on some really
                important things, there'll be a time when we&#8217;ll focus more on a broader digital solution that I think will help to augment what we do for our patients, and in some cases, make us a little bit more geographically agnostic where somebody is,
                but we're going to approach it very differently than the groups that have done it so far. I think they've tried to do too much and I think they're finding out it's not possible to deliver it that way.<br>
                <br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Jared Haase:<br>
              </td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Okay, that's great. Thank you, I appreciate all the color.<br>
                </div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>
      <div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
              </td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you.<br>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Operator:<br>
              </td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you, our next question will come from Jiten Sanghai with Corre Partners. Your line is open.<br>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div>
          <div><br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Jiten:<br>
                </td>
                <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                  <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Hey guys, congrats on a great quarter, and appreciate the questions and answers here. Maybe two for me. One is, is there like a theoretical capacity you should think
                    about, because clearly, the volume growth, the record Q2 is great, but is the system operating at 90% or some X%? Clearly, I ask the question because incremental visits are very, very accretive to margins. And then related point, as you
                    think about the de novos, how would &#8211; what is the staffing environment like? How will you attract the number of FTEs? I think Chris, you mentioned maybe a record year for opening de novos. I think they both relate to what's available in
                    the system, but then how will you recruit X number? I don't know if it's 50, 100 of FTEs. Finding them is hard, but the question isn't just finding them, it's what you pay them and how the economics works. I think there's two parts to
                    this, if you could address both, that would be super awesome. Thank you.<br>
                  </div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <div>
            <div><br>
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                <tr>
                  <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                  </td>
                  <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"> <font style="font-size: 12pt;">Yes. So, on the capacity side, think of it this way, our capacity really isn't limited, generally speaking, by
                      physical footprint. So, the typical clinic may be open from 7:00 to 6:00, but we have the ability in that same physical footprint, which has more peak times and also has slower times. We have the ability to fill in certainly some of
                      the slower times, then we have the ability to extend hours and do other things. So, our visit per clinic per day number can continue to grow. It's not constrained by our physical footprint. It may be limited or it correlates with our
                      staffing. And so, we have to have the staff available, as you mentioned, to be able to see the next five or 10 visits per day. There really is the possibility, ultimately, of getting that number up much higher than it is right now. It
                      won't happen overnight, but a little bit over time, as we've shown over the last couple of decades, we've increased that number really, ex COVID, every single year. So, that part I think will continue to move forward as long as we can
                      continue, as you mentioned, to find staff. <br>
                      <br>
                      I would point you back to Eric's comments around the investments that we've made in recruiting and retention, in school affiliations, residency programs, mentorship and other things, to try to have a stable bench from which to draw
                      from, to backfill for more senior therapists. Those are the ones that go and open the next adjacent clinic, not the new grad, but the more senior person, and that more senior person then gets backed up maybe by somebody more junior in
                      a clinic with a lot of people with tenure, so they can grow and learn. It's easier to absorb that way.<br>
                      <br>
                      Again, it's not perfect. The market is competitive, and in some cases it's tight, but we're finding people and we're growing, and we expect to continue to be able to do that, particularly with the investments that we've made over the
                      last six to nine months.</font><br>
                    <br>
                  </td>
                </tr>

            </table>
          </div>
          <div>
            <div>
              <div><br>
              </div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                  <tr>
                    <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Jiten:<br>
                    </td>
                    <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                      <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Chris, that's super helpful because what it sounds like is there's no theoretical capacity. So, the way we're thinking about it, is equity holders the right lens,
                        which is incremental visits are extremely margin accretive. So, whatever your margin guides suggests for this year using your updated EBITDA range, as we think about next year or the year beyond, there should be some flowthrough or
                        increase in EBITDA. So, your margin should expand over time as you have incremental volumes. Is that the right general lens? I don't know if you can quantify that, or if that's just a good sound bite to end on from my perspective.<br>
                      </div>
                    </td>
                  </tr>

              </table>
            </div>
            <div>
              <div>
                <div><br>
                </div>
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                      </td>
                      <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                        <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">No, I think it's a reasonable sound bite. There's certainly points of inflection where when you have to go up, you may go back a little bit before you can go
                          forward again. But generally, you're right. The last few patients of the day are incrementally more profitable. Your fixed costs are covered. I think that's one of the reasons why you see our total cost per visit come down a bit
                          this quarter, is because of that jump in visits per clinic per day. So hopefully, with particularly continued commercial rate wins, continued wins like we're seeing with Metro, with five, six, seven dollars a visit in rate growth
                          with a combination of continued efforts around work comp and other more preferable payers, that combination gives us more than enough to offset what might be a little bit of wage pressure year to year. That wage pressure for us, I
                          mean, we're well below right now the average increase that people got at the end of the year. We're getting that with some efficiencies. And again, I point to some of the initiatives around AI and virtualization at the front desk
                          which are really just now getting started, but should give us some additional lift as we go forward. So, you have to deliver it, you have to make it happen, but I'm hopeful at this point that we can continue to execute on that.<br>
                        </div>
                      </td>
                    </tr>

                </table>
              </div>
              <div>
                <div>
                  <div><br>
                  </div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Jiten:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Great. Thank you for your time, Chris. Appreciate it.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div>
                  <div>
                    <div><br>
                    </div>
                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                        <tr>
                          <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                          </td>
                          <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                            <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes, thank you.<br>
                            </div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div>
                    <div>
                      <div><br>
                      </div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                          <tr>
                            <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Operator:<br>
                            </td>
                            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                              <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you. Our next question will come from Michael Petusky with Barrington Research. Your line is open.<br>
                              </div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>
                      <div>
                        <div><br>
                        </div>
                        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                            <tr>
                              <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                              </td>
                              <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                                <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Hey, Mike.<br>
                                </div>
                              </td>
                            </tr>

                        </table>
                      </div>
                      <div>
                        <div>
                          <div><br>
                          </div>
                          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                              <tr>
                                <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Michael Petusky:<br>
                                </td>
                                <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                                  <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Hey, good morning. Good morning.<br>
                                  </div>
                                </td>
                              </tr>

                          </table>
                        </div>
                        <div>
                          <div>
                            <div><br>
                            </div>
                            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                <tr>
                                  <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Carey Hendrickson:&#160;&#160;&#160; <br>
                                  </td>
                                  <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                                    <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Good morning.<br>
                                    </div>
                                  </td>
                                </tr>

                            </table>
                          </div>
                          <div>
                            <div>
                              <div><br>
                              </div>
                              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                  <tr>
                                    <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Michael Petusky:<br>
                                    </td>
                                    <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-size: 11pt;"> <font style="font-size: 12pt;">Carey. You gave the hard numbers on the rate per visit. I'm just curious,
                                        commercial pricing, was that &#8211; I'm assuming that was up a little bit in the quarter. Do you have a percentage that was up versus the comparable period a year ago?</font><br>
                                    </td>
                                  </tr>

                              </table>
                            </div>
                            <div>
                              <div>
                                <div><br>
                                </div>
                                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                    <tr>
                                      <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Carey Hendrickson:<br>
                                      </td>
                                      <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                                        <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Sure, I can calculate that real quick. It was up&#8230; <br>
                                        </div>
                                      </td>
                                    </tr>

                                </table>
                              </div>
                              <div><br>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                  <tr>
                    <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Michael Petusky:&#160;&#160;&#160; <br>
                    </td>
                    <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                      <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">And then I guess the second &#8211; go ahead, sorry.<br>
                      </div>
                    </td>
                  </tr>

              </table>
              <div><br>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Carey Hendrickson:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Sure. It was up about between &#8211; right about one to one and a half percent versus last year's second quarter. Second quarter of last year was actually the
                            strongest quarter for commercial rates last year. It's up&#160; about 2.2% from the first quarter. So, we had a nice bump in the second quarter versus the first quarter in that commercial rate.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Michael Petusky:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Okay. And the issue in Michigan with the large payor, how much impact did that have on the commercial pricing overall? I mean, did that take down 20 basis points,
                            more than that?<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Carey Hendrickson:&#160;&#160;&#160; <br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes, it was &#8211; again, let me calculate just a second. It probably had about a $0.30 per visit impact or so. Net rate would have been right at the first quarter
                            number had it not been for that Michigan payor rule change.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Michael Petusky:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Okay, okay. So, is there anything to suggest that what's going on in terms of that payor in Michigan could be an issue with other payers elsewhere, or do you
                            really feel like this is sort of an isolated situation?<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">Mike, I mean, each year, I wish it was &#8211; I guess I wish it was uniform. Maybe I shouldn't wish that. I mean,
                            we've got 48 or 49 other states where it's not an issue. So, I don't see a contagion problem necessarily. Michigan has had some ebb and flow with this payor on a number of different fronts, utilization caps and other things that
                            have been challenged and even litigated. So, it's bounced around a bit. And we're always going to have that. People are going to try different things at different points in time, and it's really no different. But that's one that
                            we've called out this year, which is a little bit of a headwind.</font><br>
                        </td>
                      </tr>

                  </table>
                </div>
                <br>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Carey Hendrickson:&#160;&#160;&#160; <br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes. And Mike, as Chris said, there's always puts and takes on the net rate. You'll have things like that, but then we've got other things that are overcoming it
                            in other areas. But I don't see it, as Chris said, as a contagion kind of thing at all.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Michael Petusky:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Okay, great. That's what I was trying to get at. So, Chris, earlier you said that IIP felt like was a top priority in terms of capital allocation. When you were
                            talking about that, were you talking about it in terms of internal investment, hiring trainers and such, or are we talking about more in terms of external assets that you may try to build on the current base of business, or
                            both? Thanks. <br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes. Well, it's always internal. I mean, that's really not a problem, and I really don't think about that, maybe I should, but when I talk about capital
                            allocation, I don't. That's just a matter of course. So, what I'm talking about is investing in additional companies to continue to fill in our service complement to build on what we have, to give us more opportunities for cross
                            sell, and to continue to grow as we have the last few years.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Michael Petusky:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Do you feel like there are assets out there that&#8230;? <br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:&#160;&#160;&#160; <br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">So, external investment.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Michael Petusky:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes. Do you feel like there are assets out there that you're engaged with in terms of active discussions, or is this more like a couple of year, two year, three
                            year type target?<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">It'll be ongoing, but we're actively involved, and we've spent more time this year, I think, probably than ever before, attending conferences and getting
                            face-to-face meetings and being active in the space. People now know who we are. And while it's a much smaller space in aggregate than the PT world, we're making some progress. So, don't be surprised if we're active and continue
                            to be in that area. So, it's important it works. The team has done and is doing a really good job. And we like the embedded growth elements in this business, particularly, I think, not to make any kind of a political statement,
                            but if manufacturing is going to increase in this country, and I think just with the announcement yesterday on Apple and others, there's going to be a push to onshore manufacturing, and we're positioned pretty well to benefit
                            from that. We continue to execute on what we've been doing, and I think we will. <br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Michael Petusky:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;"><font style="font-size: 12pt;">Absolutely. Hey, let me just sneak one last one in and then I'll let the next person ask questions. Chris, you
                            mentioned on the last conference call that you guys had been involved in a deep operational dive with your top 40 partnerships. I'm just wondering, anything interesting, surprising, has anything come out of that you would be
                            willing to share that might matter? Thanks.</font><br>
                        </td>
                      </tr>

                  </table>
                </div>
                <br>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Yes. The only thing that I'll share is that we&#8217;re &#8211; a couple things. One, those calls have been important, making progress. I think what partners have
                            appreciated, and it was my theory going into this, is when you look back beginning with COVID and after, the year after COVID, we were both lean and busy, and it was a good year to benchmark against. I use the analogy, it's like
                            your weight may fluctuate since &#8211; if you use your college days as being this is a great comparative point, or maybe a difficult comparative point. As you go forward, it might not change a lot year to year, but the change over
                            time, you lose track of where you were, and pretty soon, your belt doesn't fit the same way anymore, and you lose where you are in space a little bit. That's one measure. Weight's pretty easy to keep track of, but we're
                            measuring a bunch of different things in this business. <br>
                            <br>
                            There've been a lot of influences that have caused certain things to happen, they're just part of the reality. But I think having now a really visible, tangible tool that our partners get every month, that compare where they are
                            now to where they were at the most efficient point, and how things stack against that, that's been a really good yardstick to see change, and then to be able to focus on those areas that need focus. So, we've used that and we're
                            making progress, and I think our partners have been very understanding and appreciative, and we're seeing change as a result.<br>
                            <br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Michael Petusky:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Sure.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Operator:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you. It appears we have no further questions at this time. I'll now turn the program back over to management for any additional or closing remarks.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Chris Reading:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Look, it's been a good call. Thank you all for your questions. A lot of really good questions. Carey and I are available for the rest of the day, and whenever you
                            need us. We appreciate your time and attention, and particularly your support. You have a great day. Thanks.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Carey Hendrickson:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Great. Thank you.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 126pt; vertical-align: top; font-family: 'Times New Roman',serif; font-size: 12pt; font-weight: bold;">Operator:<br>
                        </td>
                        <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal;">
                          <div style="font-family: 'Times New Roman',serif; font-size: 12pt;">Thank you, ladies and gentlemen. This concludes today's event. You may now disconnect.<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>

                <div><br>
                </div>
                <div><br>
                </div>
                <div><br>
                </div>

                <div style="text-align: center; text-indent: -108pt; margin-left: 108pt; font-family: 'Times New Roman', serif; font-size: 12pt;">***END***</div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div style="font-weight: normal;">
    <div>
      <div style="font-weight: normal;">
        <div>
          <div><br>
          </div>
          <br>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>usph-20250811.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.1.5296 Broadridge-->
<xs:schema targetNamespace="http://usph.com/20250811" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:usph="http://usph.com/20250811" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-types="http://fasb.org/srt-types/2024">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="usph-20250811_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="usph-20250811_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://usph.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>usph-20250811_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.1.5296 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>usph-20250811_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.1.5296 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://usph.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="usph-20250811.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://usph.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $= CL# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "OD?]LS]NC]E_\ 8 ^%</QC_:K^)VF_
M#'P3J&K3>'= N+RUO;V_\4>)X]%U3Q!'X7\.V-G#*^H:_=Z1HNJ7=EIY>%KI
M+*<1,67%?7%>%_'3]F/]GG]IW3?">B?M%?!CX=?&[P_X'\2MXQ\+^&OBAX7T
MOQIX8TWQ.VC:IX>_MIO#6O07NA:A>1Z-K6JV,#:GI]XEO'?3O D<Q610#^:O
MXQ_\'C7_  2Q\!6NF7'PQT+]H'X[2W;R)J%CX<^'R^![K257_5RR/\1K[P[9
M7D<G<6EX\J?\\FK\H/C-_P 'O/C2>?QII7P!_88T&RL986A^'_C;XJ_%B[DU
M6SG>U@9+_P 5_#OPQX5N=.N5MKXW,3:9I?Q&C%[:1PSC4[">9X+?^R+Q=_P2
M=_X)B>-?"^O^$=8_X)]_L;6NE>)-)O=&O[GP[^S;\(/">O06M_ ]O--I'B7P
MUX0TK7]#U"-'+VNI:1J-G?6DH66">-U!K_)B_P""U_[$/A?_ ()Y?\%*/VB_
MV8O $[7'PV\.:AX1\7?#@S70NKVT\'?$;P3X?\:V&D:@3))-'>:!>:S?Z"WV
M@1O=0Z9#J$,26E[;9 /T4^-/_!V[_P %D/BK;Z9!X.^(OP7_ &>7T^Z>:>\^
M#?P7T+4+S68&CGC6RU8?&V^^,E@(5:6.;S='L-'NS-;0XN! T\$W]M/_  ;*
M?$C]J+]HK_@G;>?M<_M:_&;XD_&?XC?M)_&WXE^(-#U?QQXF.HZ'IO@KX?ZP
M_P ,;:U\"^#;&&Q\+?#?27\6^%O&,5[X=\(Z/HNCW5U91ZL;!;F[EFE_R-;*
MSO-2O+33M.M+F_U"_N8+*QL;*"6ZO+V\NI4@MK2TMH$>:XN;B9TA@@A1Y9I7
M2.-&=@#_ +E7_!/?]G'2_P!D/]AW]E+]FK2H=)3_ (4]\"_AYX2UJ\T2R_L[
M3]=\8P^'[.]\=^+%LRSM%=>,O&MYK_BO4B[O)+J6LW<TK-)(S$ ^Q:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIGF
MQCDR)CIG<O\ C33/ .LT0^LB#^M+F7=?>-1D]HM^B9+14/VFW')GA _ZZI_\
M53?M=K_S\V__ '^C_P#BJ7/#^:/_ ($O\_,?)/\ DE_X"_\ (L45 +JV/2X@
M/TEC/\FI?M$!X$T)/_71/\:.>+VE'[U_75!R3_EE_P" O_(FHJ/S8CTDC_[[
M7_&G@@C(((]0<C]*J]]A6:W37R%HHHH$%%%% !1110 4444 %%%% !1110 4
M444 %?XOW_!>KXU6W[0/_!7S]NKXEV&K6FMZ5/\ %VV\%:)J-C')#;2Z'\*O
M!/A3X6:.BQ2G>L\&G>#;>"^)"^;?QW4VQ3(5'^Q#^T)\5/#_ ,#?@1\9/C+X
MKUJ'PYX:^%GPP\<^/M<\07*;[;1-,\*^&]1UF[U6X7O!816;74V>/+B8GC-?
MX3/Q$\=^(?BC\0/''Q+\630W/BGXA>+O$?C;Q'/;1-!;2ZYXIUB\US57M8'D
MF:"V-]?3_9X#+)Y,.R+>VS) /TP_X(;_ +.<O[47_!57]C/X;/9ZE<Z/I?Q=
MT/XF>(YM+BCGFT[1_A:Y\<IJ%Q#+^[ETV+5]%TF'5$8%383W&X;<U_M*@!0%
M4!54 *H&  !@  <  < #@"O\SG_@RP_9ID^(7[=7[17[3NH0V\^A?LW_  %M
M/!NEJT]U!>6WQ$^/WB-K30]2@2&1(+RSMO 7PV^*6F7]M=)-''<:YI5VB)/!
M!(O^F/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!X=\5_P!HGX6_!J[L=-\:ZW-#JNHVTUW;
M:9IME<:E>+!&0J2W45JKFSCN7+);//L64QR$?*F3\RW/_!1GX6Q22I!X+\=7
M*HQ$<PCT..*4#HP$FK+*@/HT88>E?07B7]E'X"^,=<U'Q+XG\$W>M:YJUP]U
M?ZA>>-?'S2S2R$G:B)XI2&W@C!\NWM+:.&UM852"VABA1(UCTO\ 9(_9ST?/
MV3X6Z--EBY_M2_U_7.2NW _MO5M0VKCHBX0-\P7=S7\S\699]+3-N(<;_JIQ
M!X+\(\*1Q,_[+]K2XFXAXBGA8QC"F\S>-R'#98ZU9J>(G3P4:,<,YK#JOC(T
M_K%3]LR#'^ . RG#+/<F\1L_SQT:;QLXRRC*\K6(;<JBP4,+G,L3&C"ZI1EB
M75G5C#VKA0E-TX_'^H_\%)BEY,ND_"@7-@"/(FU'Q7]BO'&!GSK:VT/4(8R#
MD#9=R@C!)!X'+ZU_P4@\:7$2+X?^&_AO29P?WDFJZSJ.NQ..P6&VM=!9#[F9
M_H*_15/V?/@7']WX0_#H_P"_X1T23T_YZ6;>G\_4U97X#_!!,X^#_P ,#G^]
MX$\,/^6_3&Q^&,]Z^#Q?A;],K&^WC/Z1O#&$I5W)^QP/!.4T?8QD[J%#$+(%
MC:<8[1E]9E5M\51W;/IZ''7T=\+*E*GX09Q7G22M/%<08RLJC22<JM&IFU3#
MS;U;3I<E]HKI^6)_X*(_&_MX?^&6.V=#\2G]?^$P&?R'TKG]6_;X_:!U*)X[
M.]\): [@[9])\,Q32Q9Z%!KMUK4!*]1YD,@_O!AQ7ZX?\**^"/\ T1[X7?\
MA ^%?_E51_PHKX(_]$>^%W_A ^%?_E57RM?Z/?TM,33G2J?2?K1C--2="&;X
M6HD]^2KA84:M-]G3G%Q^RT>U1\6_ >A.-2'@I1E*+32K1RW$PTM\5/$.K3FN
MZE!I]5JS\8O^&U?VF?\ HI?_ )9OP_\ _F5J*?\ ;._:6N(GAD^)DRI(I5C!
MX5\#VLH!_N3VWAF&>)N.&CD1AV/)K]HO^%%?!'_HCWPN_P#"!\*__*JHV^ O
MP/<DGX/_  R&1CY? WAI!^ 335 /N,'O7SC^BE]*)II_2GXG::::?%GB'9IZ
M-/\ X5W=-;JVIZT?'3P3BU)>"&31:::E'(>$KIJS33^H*S3V=ULOE^#E[\?O
MCE?W,EU/\7_B5'+*<LMEXT\0Z;; _P#3.ST[4+6TA'^S% @]N!57_A>7QL_Z
M+%\5/_#A^+O_ )<5^\S?L^? M^OPA^'(XQ\OA#0T_P#0+)>??KVSBLB\_9B_
M9_O@PG^$_A! X8'['8-IQ&]=IVG3Y;4H0/NE"I1OF3:W-?+8GZ$GCY6G4K/Q
MYCB<14DYSJ8G..,U.K.3O*=2K[6O.4I/5R:DV]6>_1^DIX51482\,JU&E%**
M5'+>')J$4K)1IMT8I+9)222/PN?XW?&F12DGQ?\ BE(AZH_Q!\6LI^JMJY!_
M$5AW7Q(^(MZ<WGC[QM=GIFZ\5Z].?SEOWK]PIOV+_P!FB>5Y7^&<:M(VYA#X
ML\=6\0/^Q#!XGCAC'^S'&JCTJ/\ X8J_9F_Z)I_Y>7Q _P#FJKY?$?0A^DW6
M<HS\5N%<124I*#Q'&WB!>4+OE<J;X6JQA)JSE%3FHNZ4Y)7?M4?I,^#="TJ7
M!/$%"=E=T>'.%86=E=*4<]@VK[-I-I+1;'X22^(-?G;=/KFL3MS\TVIWLK#.
M,X,D[$9P,^N!GH*B_MG6/^@KJ7_@==?_ !VOW@_X8J_9F_Z)I_Y>7Q _^:JL
M;5/V%OV<]01EM/#&M:&3C#Z7XKUZ5TP,?*-:O-70YZG<C<],#BO&Q'T"OI#6
MG6?'/ F*J[N,>*N,G6J-+3W\1PE2@WHDG.I%;:V6GIT?I5^%<I1IO(>*\-#^
M>>39%[.&JWC0SZK/S]VF]NY^'']LZQ_T%=2_\#KK_P".T?VSK'_05U+_ ,#K
MK_X[7[-2?\$\_@7(<KJWQ&A']V/7]#(_\C>%Y6_\>[U'_P .\/@=_P!!SXE?
M^#WP]_\ ,G7BR^@S])",FEFO#,TMI1XOS%1>VJY\NA+[XK;T/57TG?")I/ES
MF/D\BA=?^ XAKHMF^A^-']KZL>NIZC_X&W/_ ,=IO]JZH>NI7_\ X&7'_P <
MK]>M2_X)R_#29'&E>-_&=@Y'R->QZ/J:H?\ :2*STPN.V-ZG_:KFO^';.@?]
M%7UC_P )6R_^7=>-B_H5_2<P]10HX+ X^-K^UPG&N A36VEL=B\%5N]]*;6F
MK6AZ5#Z2/@W5AS5,VQ6%EM[.OP]FDI]-;X;!XB%O^W[Z;'Y5?VKJG_02O_\
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MWE6 ;?JWA[L]2_X7E\;/^BQ?%3_PX?B[_P"7%=WH_P"UO^T9H</D67Q2UF9
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MH\295Q;PA6FX*KB*^ H9WE=&[IJ;^L93B*F9U(P<IR]S)>:5.FY*/M)0HO\
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M[^\74=,_:RC\<VUK9:8BR:A?:J_P_P#V5/%/]BV-K&ZO+>:N+&V";F$I".5
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MRU;4K^T\->'[33/]!.OY;_\ @\ _Y0[ZV<<C]I+X'?\ HSQ30!_&7_P;-?\
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MN(>WT+PKX:TR)I'$:+9Z/HMA+*5=HW,G^FU_P2,_X-J/V./^"?/@_P .>/\
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M_2X\*_$.PAC2"?X@_"^YG,=\FG7<ZF?6?!^I1/J?A6YG-I;ZCXBTR*/6YO\
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ME%2Q"IQBL;@HN23Q=&G&=".N*I1IQEB)?9M%%%?VX?S,%%%% '^<K_P>_?\
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MO\H *_SAO^#P3_@EIJ7PX^,6D_\ !3/X5Z+&WP_^,4NA>!_VA;;3[:_)\/\
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MKZQO+>18K[1?$&A:K:7^@^)_#6LVMAX@\+^(],U3P]X@TW3M9TR^L;?V6O\
M(N_X-_\ _@M[XU_X):?'.Q^'/Q.O=4\3_L8_%WQ+8V_Q-\,K<M+=?#'6=1>W
MTX?%CP?;3/\ 9W>PB6W;Q;H):W76])M%GM+JUU*S"ZA_K@:/K&D^(=)TO7]
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M#X>ZA?6FIPVYGMM<\.>%5\5^&]7LXVT_6_!_B3P[J5E<75K/#.X!_3;1110
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M?49[:[O-&T?4+ M:V^M?#;5M3;P=XD\+W_V7Q#HT5OH6M75E+X=\5^%-?U\
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M?PROH_BSJMM!>"5/L&H?\)=X8\ SQMLE^U:9#J]J559"X_RQJ_LJ_P"#SO\
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M /\ /L_X(X_\&Z_[5/\ P4QU_0OB=\2-!\5?L^?L>[4U&3XN^)=%_L[6?B=
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MN_\ 2/[X.?\ @P^(7_S:4?\ $/-_P1=_Z1_?!S_P8?$+_P";2@#]8_AO\2_
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M?EE"?+>EA*,I2M*:A!U\1-RKXB45*I-J,(P****_4CX4**** "BBB@ HHHH
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M@[0/"WAG29M<NO+3P7K]Q86UKJ.J7'_"/:A=0:K<Z1_;/VG_ ,'J_P#RBV^
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MUGX=:]J&AW,1N;'5_#<VC:YI]U+:ZG&0 ?SR_P##57_!Y9Z?M,?^(Z_LI_\
MSK:^/?\ A]7_ ,'+P_:./[(G_#1/Q2_X:7&LGP\?@W_PH?\ 9=_X3(:V/#__
M  E1TTVG_"H/L_VD>'@=6*_:L"T^;=N^6O\ 6*K_ #8S_P KJLW_ &<Q<_\
MK(4E ')_\-5?\'EGI^TQ_P"(Z_LI_P#SK:_LQ_:1^/O[4GP:_P""&/Q._:-U
M;Q1KG@O]KWP!^P]<_$35?%NK>&_#2>(/#_QCTOP5!?ZCJE_X6OM#G\)K?VNN
M+.\^DW'A^31@X: Z<;;$5?LO7Y7_ /!<'_E$-_P46_[-1^+'_J/ST ?P1?\
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M3PQ)J5[IGAR:P\.6^BZ%I !_7">A^A_E7^63_P &YWPL_93^+O\ P61_:_\
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M$+X;:OH5EKC6T@TRYUC3+'X.Z7>7VFQ7?E->6]KJ%I<20!Q%,KXS]?\ P/\
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M^#!#"++P?K-Y;^)_$B^)+?1IUG&C:G<-9WMMILT6ES"YBL[>8 'W;7^;&?\
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M=3T&X_9\^"*7]GXBT_7(IM(O-*GA)2[M]1BDM98R5E1E.*_O=_X8<_X(5_\
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M_P 7:O>:_P")M7O]=UJ_<27>I:E<275U,RJ$0-)(3MCC152*) L42*J1HJ
M4M/T[4M9OH=/TJQO=4U*[=EM[*PMI[V]N7"M(XBM[=))I6"*\C[48A%9VPJD
MC[_^#_[ /C'Q,UMJWQ4U%_!6BMN=]"TXP77BJYV30*(GDD2?3-)66+[7_I$@
MU&6-TMR+":*=I(O\G>).(?I _3+XJG2R;)<=7X<R[%?[#DF!JRP7!W#<)^[3
MKYIF>*E1PN,S:5%N=7%8J=3'U5*M'+<'A\*XX2']XY/E'A5]'K(5/'9AA<-F
M.*I?[5F>,4<1Q!G4XZRI8/"4(SQ$,'&HDJ>%PU..%H^Y/%59UN?$3^$O#/A3
MQ)XSU>VT'PKHNH:]J]VRK#8Z=;O/*=S*GF2D8CMX59E#W%P\4$>X>9(H-?I;
M\%_^"?D3"SU[XT:C(ZE8YU\%:%<M!O),;B'6]:BVW"1[!)'/::0UO<[G5DU2
MW:%HYOT)^'GPJ\ ?"K2$T7P)X:L-#M>MQ<1J]QJFH2;Y9/.U/5KIIM1U"4--
M(L1NKB1;: I:VJ06D,,$?H5?VUX+_02X%X,AA<Y\3:F&X^XDBJ=5Y4Z=2/!^
M7UE:7LXX.M"EB,]Y97C*KFM.E@Z\+*644VI2G_-7B+]*+B3B#V^6\%4JW"^4
MR<J?]HSE"6?XJF[KF52FZE#*^9;+"3K8FG+WH8Y/18GA[PUX>\):5:Z%X7T7
M3- T>R5UM=-TBR@L;.$22R3R%8+=(TWRSS33S2$&26>66:1FDD=FVZ**_O##
MX>AA*%'"X6A1PV&PU*G0P^'P]*%&A0H4HJ%*C1HTXQITJ5.$8PITX1C"$4HQ
M222/Y9K5JV(JU*^(JU*]>M4G5K5JTY5:M6K4DY3J5*DW*=2I.3<ISDW*4FVV
MVPHHHK8S"BBB@#\Z_P#@I;\$?@UXH_8L_;=\?>)?A1\.?$'CBR_9"_:'NK/Q
MAK7@KPYJGB>TN=%^#'C&32)[?7;W3IM3AFTN2&%]/DCN5>S>*-K<QLBD>%_\
M$2?@I\'=*_X)B_\ !.SXC:9\*OAWIWQ O/V1_@MJ%WXWL?!GAZU\6W-_J7@+
M2O[0O+CQ#!IZ:M-=7WFR?:YY+MI;G>_G,^XY^[/VV/!?BGXD?L9_M;_#OP/H
MUSXB\:^/?V8_CWX+\(>'[-H$O-=\4>*?A7XKT/P_HUH]U+;VR7.IZM?6EE U
MQ/# LLZF:6.,,X\B_P""6'PJ^(/P,_X)O_L0?!OXL>&+WP7\3/AA^S-\)/ _
MCSPEJ4ME/?>'/%7ASPCINF:UH]U/IMU>Z?/-8WUO- T]C>75I-L\RWN)HF21
M@#\-_P#@D]H]C^SI_P %!_VH_B#!?7$'AK_@H5_P4:_X*R?"#Q9!J']H:JK?
M'?\ 9L_:2^('Q!^$4?AN.S6#3/!VC:C\&+#XY)XRU'7$OY/%'B32_ASI&EW^
MF7$"Z;K&S^T'X0'QJ_X+9_LE_MA7\MY=:'\$OVY/!G_!/GX+,PU?3+2W32OV
M%?VU_P!H#]I34HK*23^PO%5EKWC7Q1\']&TGQC8I-+8WG@'Q-X4-Q'/INHVT
M?K'B[]C;]LG3?V"?VR[_ .#OP^;3/VP/A?\ \%;_ -JG_@H#^R/X0\37FF_V
M-\4+2R_; \0?%CP-8:@;'7+!+SP]\8?A%J^NZ;I^C3^)/#4L^IZUI5CXBN=.
MMX=3L6^A-#_8^^-_A+X>_P#!("RNO!\^M>.OAE^W-XN_:E_:UN]&OQ/HW@SQ
M1\:_V;?VS+_XI>(;)-:U!M2B\)1?'#XWZ7X;\/:#:3:O=^'M*U?2=,B#Z/H\
MUW; '[F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !117 _$+XG^!_A;HLFO>-]?L]&LU!$$4C&6
M_OI><0:?80A[N\F.UCL@B<@*S-A5)'%F.99?E&!Q69YMCL'EF6X&C/$8S'X_
M$T<'@\)AZ:YJE;$8G$3IT:-*$5>4ZDXQ2W9U8+ XW,L50P.7X3$X[&XJI&EA
ML)A*-3$8FO5D[1ITJ-*,ZE2;Z1C%L[ZOCOX]?MC> _A''=:)X>^S^-_'7EA8
M]+L;R/\ L;299/L[I+K^I0-(T8%K.US#86,<]U=.D5O+)IT-S]O@^&OC5^V?
M\1/BU>2^$?AA8ZIX4\,7H>UBMM/C>Z\:^(3S)(;FXL&F-A 88B%TO2-[A#=-
M>:E?12116D/PI_80^)WCAH-3\<W4?P]T.2022I>P?VEXENX_G9A;Z6D\,-LT
MQ55^TZA>1^4LPN4M;TQM;/\ PMQO]*'C;Q&QF/X(^BSPEF?%>8TZD\%F/B-B
M<#3H\/91*3Y/:99+-51RV52S=2ACL]J4,-)0Y\-EN8TIQJQ_J/ACP0X:X.PF
M&XH\<,^P62X5Q6(PG"5+%2GF&,4;2]GC?J3J8RJ^E3!93"K52:]KC*$E.D?,
MOCWXE?$CXU^)QJ/B?4=1\1:K=R+!IFC:?;RFSM$5IW@L=&T:T#K&L0GG"%(Y
MKN7S)9+B>>6221OJ#X1?L'?$;QH]MJ?CZX'P_P##[,LCV\L4=[XENX<,=EM8
M"06]B9-J#[1?RGRDE$R6ET4:$_J#\*OV?_A;\'+)(/!_AV(ZEM7[7XEU@QZG
MXDOY!';QN\^HO#&MO'(UM'/]ATRWT_2X;EII[:Q@DGF+^T5YOAU]!K!8K,9<
M8^/G$^.\0>*<?56,QN4X?,,>LJ]O)\TH9EG%65'-\XE%V7+0>5X6G:5'V>*H
MJ,WU\7_2>KT,(N'_  MR3#<,9/AJ?U;#9CB,)AOK<*45RQ> RNFIY?@(V6CK
M_7:DDU)PHU+I>0?"SX$_#'X.V"6O@KPY;P7S1HE[XBU';J'B/4F"0J[W>J2Q
MJ\:2/")_L-A'9:9!.\SVEC;^;(&]?HHK^\\DR+)>&\LPN2\/93EV291@::I8
M/+<KP=# X+#TU]FEAL-"G2CS.\IR4>:<VYS<I2;?\KYGFN9YUC:^99OC\9F>
M/Q,N>OC,=B*N)Q%5].:K5E*=DM(QORPC:,4HI(****]4\\**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHH)P"3P!R2>  .I)H *J7U_9:9:3W^HW=M8V5L
MADN+N[FCM[>&,<;I)I65$&2 ,L,L0HR2!7SG\2/VF?#'A:_F\(^ ]*U'XK_$
MAAY<'A3PBCWEO82R+/Y<NOZS!%/9Z;$KPA7M8S<:DQFML6D<%PMTGA3?L^?'
MKX_:@NJ?M"^-T\'^#Q.TUM\-_!<D<DTD#23W%O#=3YFTRR-M*;%TN[T^)-0N
M([5H9X=/NUBO5_(^(O%3V>*Q&0^'O#>8^)/%%&K/"UZ.4U:6!X5R3%Q;C.'$
MW&>+B\GRV>&:G+%9;@GFF?04/9QRAU:M"-3]&R;P_;PU+..,\YPG!615(1K4
M9YA3J8G/\UHM*47DG#E%K,,7"K>,:>.Q,<'EBYU/ZY*$*G+'\7?VXH$OW\$_
M +0Y?'7B:X\VW/B4VL]UH]G-N@5&T72[>-KKQ!(%>Y\R\N)-/TNSDBM9D_MJ
MWGGCM_&?"7['OQM^-NLKXR^.WBN_\.6UPXD>WOV_M;Q7<0I-!$]G::<98]-\
M/02VT,J17,[3O \=K+_8U]#*S)^E'PY^#?PW^%-C]B\#^%M.TEW2)+G4C']J
MUB^,)N#&][JMR9;VX9/M5P$#S;8TE:*-5B"HOIU?F];Z/^=>)>,HYO\ 2 XQ
MK\5X>E7CB<%X:\*5<9D'AUE$H2C*E"LZ4Z&><38BDX\_]H9IB,-4<ZE6C&BL
M)R4(_8Q\6\JX+PM;+/"3AV&1U*L'1Q/&>?PP^:<6YA%KWI4XN-3+LIIRT2PN
M&A7HI1C4Y8XARJ'C?PM^ GPN^#]J(O!GAJVAU%E"W7B#4<:CX@O#LA5C-J4Z
MF2&)G@686=DMK8PS/-);VL)FD#>R445_1V29%DO#6687)N'LIR[(\IP4/9X3
M+<JP6'P&"P\-VJ6&PU.G2BY.\IR4>:<FY2;DVW^,9IFV:9WC:V8YQF&,S3'X
MB7-6QF/Q%7%8BH^B=6M*<N6.T8)J,(VC%))(****]8\\**** "BBB@ HHHH
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 11,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">U S PHYSICAL THERAPY INC /NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0364866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1300 WEST SAM HOUSTON PARKWAY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">HOUSTON<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">297-7000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">USPH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://usph.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>usph-20250811.xsd</File>
    <File>usph-20250811_lab.xml</File>
    <File>usph-20250811_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "usph",
   "nsuri": "http://usph.com/20250811",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "usph-20250811.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "usph-20250811_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "usph-20250811_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://usph.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20250811to20250811",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250811to20250811",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000885978-25-000044-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885978-25-000044-xbrl.zip
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M'T_I!EAR>6>20^P[Z%3%<X@+G)RMC)N)9$V^A:EF;2$3\=KH)9<8:D;381$
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M:.339CBFOAR!A:;<<&)@NDJ$N+#K^++P5!5E=QY$YUD=.PV2D75W_=#W*QM
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M#3I65KW/HM(I&[*KOCH<E=MS5&YMILWSG8A7(;QTXI8-DLBXBIM^92;'HQ3
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M3Y+OTE_;"W%#GW,;M%GR;$FCF::#Q=:[>ECMGN8_?NB=K76PL/Z<XRR;0G;
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M9A]'0=T]<-'26S"#YJ4M+F5GR0E1RF\!/V' WDW!-2_/'=2HQT\YL/[J7Y,
M16$22"'8>4H\U[%#NH"]M6UP!)/GIFBPZG3*BTV#'BXZ<.OZ6 1(3 1D$EIE
MY!IPP3?_^F_$2YM6Y*%'*G%?98#15K:0I+(@;(05&_<<N8-/EAQK!)&M0I@T
M"E'4,J#$8$IM=[-/'#H^7F&'!'([R/- "_I*>&D'\$O.H[R@+5C!J(MP40*(
MC9!1XLW9RGW80TD)W$FW-!\TKD*H<^SC5;HYHD%AOPR?$YPDG&D& C<-EX2(
M1-V> (;J^0('A&:4GW1IM3=]./N.V]BKKIY<?O'CJY'O =_ U2?!-HJ+$5*.
M$"%HVT#R3+W[KMW<65C7EFY86(@@3("*#M[ 4!%Y*1&K&B(?@8.E=')(IZZS
M/"^JM @7@GQ^RX'H>530"@UO)"[-1Y]91]O"^*8.*_1?9P;>O*.#.B#H$/]2
M^9R2W<92+N>8C_CMH^TO\92(DA<,F4XQ%R2A8%(#W*BUG$J#)M=$8>FWZLB3
MVILF^!MYS4&^:3X0C@I\[*%*!!!S 7LO,'(MR"%G:#:3R7#"A^,^K5<%<L2R
M4:C^T/<Q(I$E% -X.%:1)0OM4RFS!;;30]!XI9_]^,Q747UO:XF!/*MK"Z2)
M.]4<W6.#"L$7IK2IH^=H"*NQ.W1?."9M69/M2!8"%,4PI>S!-;EMKDDOT'(M
M .E'[JXH:"O.;RXZ?2<BK@!)<QZ.PJ=P% X(&%BE_T@KVO>O+!HZB!;^X57R
MRDS;2I7^ 0'S:1Z/:&/<OA,20U]&R;S=U%L*(C0[_5%+#2(\3!VSBDTUN).6
M-4KLP=E,?BPG'G&,;,L94[[I8R;L*B7O2;_TDHPQ$(2_SQU0!^J1T!TU(V<T
MM$]5*U6?PQ[.$OQ?C<LJTBVYH^F(@US,MN)"\_RHJ/$&Z\<IG1XC51<<EBJX
M&*F6ICW"VW4F93O<RJ%@?AZ.I=UW35;J'O7IO^[[N*%S)E"G46@,SH? I"4D
MCPJ&[?;K&S@/N2FG<%^R2DI I.$1RD5KQN_PJT4('O",&9?%7_F6;F&E(>"B
M5T((IQ:G0M!,64[^:LVOZ>9 7!'4HAQ-?6,K0'_@68KPI-7FADNNLU3C.8WA
M2H+/82*,;.#WUC$)U0W/*_S*P7Q,(K$'\5K(Q[0MR96C+)_G3:CD=ZTXN&P%
MNU(WI.8SI L%.:4;$T&((AA7)TU^$/R?A.#_%+(7',5@H3-Q=8G3],*,I43N
M7M0P)D=,(HL**)G8:&Z:A0N);M,[9XB8LPC16K"&Y(6I&1TQOA+ )"&&@L7'
M@-3G'F>C1%*8J$!E.>_[EEG6'+WQ(O)&&Z_,&$[B!LX4:OU(CF]W1SJ(@Q,O
MN$@V$K9,[87G+;A\3\(?$@^;+DC &2::X9A9I[DBL[#P$L4TDI>V:)?F2#0/
M322J=1N),PW!:#CR7&TTN*N-?R90<:ZM%8 _A<@MWU=I%%X X><5:O0KKMSA
MI"\/1!6C5".2=]PV!A$4^1?/H AQ2$;0BB4O43B+[DA)9I8\%0PEK3FDS1.K
M,>8HW*9AEZKEUE"H=41G*,FJQ[QJO/6VWY]K7R]='S3IE2=1*5O[9DFIM.V2
M*9*U'B>OL0TT7X/P%FNI6B<4^M>#AD@USA@,%))J>N,HHBTP'IDK)=!)I:$Y
M<ZN(OL1 . 6#3!Q'R :&YN"YPH.\3C<2/*.[G0UL?MS<2!]YV$\YMK'/B/F5
M02*H@8O#QVM%.U*ZAS')&:PY=\+E*KV )C?JTD8JV4B[I6FK3$=.3W<8C\1V
M"4<H8H-PU]US5B*7!:NNEC: X'T^:-1/0J->@]?L(]>J/PN="Z+9PA8IIK!:
ME.+&>*_%>21U)Q+'E>&FJ0"D2?Y)IBML9+EE[1(/?)3 GH#6C+D8J"@U9\$#
M:<*V+KHQF)A0S,O<1D+[V]+E_@G=>V8[37P]71-2PS"W8V4Y\OD;SK\B0PH:
M!<D</'@8O[(Z:.[M5=(W\K(.Y! +I9C[/7AO BM24LJ=MS^(E$]"I-SZZ,R(
M<=-1*E@Z(9@Y)]] -J?DHRQD^"B%(WD6\XF(<5+YT,-(X( *5T_2Z6]MKJP>
MY.PVCEU7(A0^@)-W2>!E6$/0 LLY3$B;J)NF0W[RL-8._L*/KHQW(1@OJ#Y$
M-"SQ)>J5O3 >#*+>2<?*5G"%TDZQY\YW*>VEU>2.MO8>>!7E'E$IJ:))!DT'
MI$7"E>4MUN\7V%* L8O%LST+3%5Q\D744=D91XI>]2PQ+)XGIC0SB#-&[[>;
M&J$6YM*J.$7#>*G&VH-L^R1DVZ<0@' I?U^OV)ATJ14.R8_D6J6*1\8IYL_@
M<,BU[,,P$IG=?_?'%]H-'!@]!U5V!2::ZJJW/NE6B 1K"Q0W@SZX%GH,^4VY
M1(^G"YH$!2N(U\4]O@.FCTG'N9!R$8A_&.^!!KI6PBALR#USXJM6CXQCPG&\
M(T#@N+"+D5\L< ^BXI,0%5N>U:> :/A%"[,D>3N*U6P4KKG7Z?<=\&[J?PB8
M$[]'S<;%:A!/R/EGI6GZC5X"LM'9"FH=K$TP:NB[RX'6!^<RM.$Q2\,NQ7L&
M"T@$)JA\V53R,4 _(KI-SO4?W#Y;V\PGDTKS0DOVFQ )HR&O73VXLU)"A;A@
MGB&?Y*5@.Z854XTR_O9D?'SLYR/BR';CX.@I0%CJ#=(+TK<>C!\>;\]#IS3=
M%R+BEKD8K?3-Q_1-=Z$FKEPNQE'K77HV:5X/SD>5W&6>EVP)>+=QK3PJHP33
MKF2G1AZ(/%M]QC)EP)[+WB'K#P.[;KC$7"ZOH^M=ZE$]^%H)H>'1GHFL!CR-
MIV5'0"]QS-<:CJ27B$QGMOFW]E^]Y4)'F%'ED/6]Y@]ZX%/0 [?:'8:D%XI$
M^$=ZK%!?H_:4EC@SVAK;B>2>22]PL/28JLSXROF&H.R,,]I\=KY*_KMNQ7ID
M-RP7GE VU!@A5X%)U3\#$JI[^_%0U![YAJSW+"$M!+@:V1'):HV3K_,L/!@-
M4#@CD1ET/ZE=C40T$."O#_5TG\3IOOE6WA[>P%<M LO 7S"AK^\OX2T:918=
MB>5S<OQP?/^^B_6.XEW/\1.);FLH2,P3?.7AL>\4F+(-,&1T!(!1_Z[C4&<<
MTUO0.S8,%7IZ2K>/#RY$@ 2L.UED_X4[)S0B,I@0F>9XM<L:YG6LX)WZ1AK3
M]P9?5":N'FG,W%8,1SQW%4 Z"RY;SFP*?/14\P^XK_)^>8;ZBHJ9.I3/ 2>L
MF!VM$#X_,#;> HEQ8^R!ZQ&*_G21*C9!245]V]-:T8F';7D;MN4MCVPJ@E:Z
M1!U,LT]A1Q^**%!$\4.*@-?W*0?'8,&]!@ W72;/BS2O#C44G^KIB/;%[3L@
MWR/[/M_#(>KJ9GWAQ%A:#;IR6^T.SB74+E1(%OR%[^W.<6)Q_B.J40F4<IP3
MX'ZCO$=6F,0P(ES5^HS:0&1"JM][+*51VQ3N:%OUTUNNAPP'3T$Q:ICU07P8
M.'AKBUXUC'Z:>5@/PAEKQR'*L'XN:2ZQ@B!&^!W>H8O-K#W1*%CL"CMG-U&2
M]=Q8RM_-,A61U$4[O"9[>%S.6+ABY>UWC[".PKN2A8* )8,QF5I!>L^0%V8K
M96$ZB*U/06S=<C-U@$:4#C#+ZJV_]P#ZX^1')G]DPH.IIH!$DIU)Q;_O0QX"
M(@BIS-IBA *R\%U.KUD&+S,SF:<6\)2DP EMGUW-P7/S)4@?A%5,[N#4,=TC
MF#;P]W5>^]:F$?6I=F1RB*5^2^E+ :FS@!<VU&\KDN[<F8L168C[< B*Y.!L
MQH5TCKP @(5[RFZ4)C,2["FM\C3YU4Y&4BW 5A+CG%K.XTD;=AK3KS;D\5QB
M:'L2 $'P4&S,N\S\(J>_/#P>)3,$D7\WE4V^/?^&YYD'J1C*(/T\;RCC,3)>
M>$Y>XB;\YWN94$[)GT^/,:OWCT<=,@A=#!B&*C<S5T:WLDPN IZFP$[$:5E/
MFZ&ZPX7$2#70*&BPMLIV]<#5TK9*""^8ZB1?3D;*QH?O0YGJ7I3VB9I?*YFD
M,RZA2!N/NF\TUH\2#@DN>L8?#"[_G=5:(XK.!S&9ZXN#]?*E'$.:\N'QI9':
MV.J@/SX)_7&KS=Y?''Z1!-R,O;MSV_ F!V-036M?0MS^*$H!K#!LS@:&S['G
MSF,,J"M5X8YWG+Y?M9."A*724O@TVPI%IRIQ(_[ER[S"(4M>GB. R+5&G(K'
M$+<E!VPZZP#G#C JHQ&ZS6(30S.<$5QR55=)>FHJR Z&6TW:O& F'1F35*^F
M2-@+[@O5<T<2:H]HYH"I</9KW=*0/3PAKQ*N7TW!P39C*[K>85E[]CB?*>S8
MUB#LWX'T%XGWVN=3I^ X0GM)H=;/T2Y1*?W]W+HW\GA9ML/-&Y0'D54PDJNW
MKG+,?NXV>$*)/.SW:,XF)'HR^:QK>6E#R]F@.CKF>JB?&SEJN9'K\=@!,]L!
M8*[#_Z*8@2:.C1'PGX(QMC3%^\ZG^LOZK=EZC=D.,OI@X_\!B-QKKB#0&L6S
MGF6$8M-6R/:LM&O#V5IL5K"9^7T2.DAMJE&+[R%LQ$IT4 86LWS$66)6(H<B
M0<<'6G[7BD_DK\5GH ,]1,_5.^HJ/!$3R3*E=5-AXB3D5PF_ZQD<B"7(#]3L
M8S@8V<B-M(I-A64.;24]]YG$"]3TYFJ!J5FQ]+/,D4_&HJL!\!U07(E%1-80
M=%!X=Y;--6TUC[*#"/>6)]^!Q/UOK6T&D<:X*[YY>OP%*3;M&,-_H%NAC$NP
MSV"M ?O"*.[&2N^[%")2!U:1[M_R%3;6\ZGP*6:F($\!ULI$"K.$UU!+=<.G
MZF YQ T@?JL5I@@A&BD.FVQ$'&N_4+,$D[U!LGYA_29TY"+<!1CJ@.MBL2U)
M<<-P&.!ZF"JN&Q;$A2*XU9H08."TRE<1='L=83]Y!?+:+_=&ZJ3!5TEC/8*M
MKQR'4 =9GLY+6VM$B&<KI@MT_897H+NP*Q@,= *:JIV*Q<&D@60+@>)QVI*W
M59D5+;+6I<R<]\@VD6-*A$^,WK*.'C8?J*D1MX3=HHF4'_N2;C97*OR*/@%
M 81Y<':-U.<QR1\X6'D!ZY5W(/EC:5ULR6^<MVHAA:,C,3PN8F'\272 $^[@
MPRPQ.UIW#_[U9T-V1F4=H:Z6F .*R85#H7C=[[A =<K6Q3]R:9)!>\LMM4 ^
MG(V12,.)D8M8"KERR\%3,#_JL#WHMG69"V0J0L?H#I'LW/J*3CJZ"]B@KA,W
M8VQYKYC&1!=LO[IV7%;J!.<?XAYV\JLLHN,?J*7FW3,?@NSR$H*QWP);826
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MAD94BGSU<K'8>)CZ+&^D]3/G3V?Y&Y,QF-JU$;K49H8^;-TG;I791!Q<4SM
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MA9K7W[ZUN]WV=><G0RI70?K'>?>JW?G<N^Z<H(LF+-F::AT*;&@[:>+K=^T
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MJ>O/INT[_B(^^\65;Z4'?<05*G.7(O!/8O07N">)ZW-G:A6R7@]2,#C\\DK
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MIGA]??5?ASX7"TT21L&/3X]?;5#G:V(<"UAZI93]VN)<S47J6(>!,<^1)+6
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MUW&GF[AR-X/6\NV3K"2Y_@-02P,$%     @ +H,+6UKGNO%["   ,%8  !4
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MMO([-2W0J6F!SGNR@$[JF1;H/%D <H_/5GZWI@6Z-2W0?4\6T$D]TP+=)PM
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M1/P1/\_^]#]02P$"% ,4    "  N@PM;7/CCP^-C  #!( ( "@
M    @ $     97@Y.2TQ+FAT;5!+ 0(4 Q0    ( "Z#"UMX<@L;J!0  ."*
M   +              "  0MD  !F;W)M."UK+FAT;5!+ 0(4 Q0    ( "Z#
M"UM#I@:!30,  *,/   1              "  =QX  !U<W!H+3(P,C4P.#$Q
M+GAS9%!+ 0(4 Q0    ( "Z#"UM:Y[KQ>P@  #!6   5              "
M 5A\  !U<W!H+3(P,C4P.#$Q7VQA8BYX;6Q02P$"% ,4    "  N@PM;;9LP
M^-H%  #I/@  %0              @ $&A0  =7-P:"TR,#(U,#@Q,5]P<F4N
9>&UL4$L%!@     %  4 -@$  !.+      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="usph-20250811.xsd" xlink:type="simple"/>
    <context id="c20250811to20250811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885978</identifier>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20250811to20250811"
      id="Fact_7e35e02eb3b440679f617ee5b3d1a5a9">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="c20250811to20250811"
      id="Fact_a2e4d9c598ba487483fc8aa82102cbb0">U S PHYSICAL THERAPY INC /NV</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="c20250811to20250811"
      id="Fact_a167f776681346a0851f86938d06d9bd">0000885978</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20250811to20250811"
      id="Fact_d9d4767fd6d643e593cb717ab15020cb">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20250811to20250811"
      id="Fact_a6a12890b9334edfa3888289aa10c5e1">2025-08-11</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20250811to20250811"
      id="Fact_7191910cbf104527b4da5a81a713f023">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20250811to20250811"
      id="Fact_213251cca7e747ad809c5b90b9feb157">001-11151</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20250811to20250811"
      id="Fact_3cb6fd416d06454ab267ea8a751fdfe2">76-0364866</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20250811to20250811"
      id="Fact_c1e7f97bc7244f64b3ed48451255bb10">1300 WEST SAM HOUSTON PARKWAY</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20250811to20250811"
      id="Fact_373f109e946341e5bceb1cebd1ca8352">SUITE 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20250811to20250811"
      id="Fact_39500760d46a415b9e532222041d50ee">HOUSTON</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20250811to20250811"
      id="Fact_a507f61819aa42a1867241fc2610bf6b">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20250811to20250811"
      id="Fact_133af51064f04ce1be51ac6af5f1645e">77043</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20250811to20250811"
      id="Fact_d7ba098e84c1432aafd1cc385931a99a">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20250811to20250811"
      id="Fact_0f3e8a70311541a2b69fbe9748479a6d">297-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20250811to20250811"
      id="Fact_39af643fc99545a79de5a7906e669420">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20250811to20250811"
      id="Fact_2224c71288a443e0ac29addbd2c22ccf">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20250811to20250811"
      id="Fact_1877519efbb54991a0940350f1169044">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20250811to20250811"
      id="Fact_1dfe45420b104c3baed80ce9e35d5aec">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20250811to20250811"
      id="Fact_0e70eeca290d4127bca071bb34bf10ff">Common Stock, $.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20250811to20250811"
      id="Fact_9e83ea122502494c9e122fafb2ecbed8">USPH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20250811to20250811"
      id="Fact_095b2c21c9624aeba7a630a0bce221f2">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20250811to20250811"
      id="Fact_250369beb79e4c3e95202eac5cd50c53">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
